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ABSTRACT 
 Microencapsulation of therapeutic cells has emerged as a major modality to treat a wide 
range of diseases through protecting the encapsulated cells. However, in spite of numerous 
refinements in cell encapsulation during the past decades, the strategy still has not met the 
requirements for practical relevance. Biocompatible microcapsules (MCs) and -spheres (MSs) 
were fabricated as advanced drug delivery vehicles for various applications. Novel precision 
particle fabrication (PPF) was employed to prepare MSs and MCs with controlled size and 
uniformity which are critical parameters in the release kinetics of drugs including therapeutic 
proteins and cells. Furthermore, core/shell MCs containing therapeutic cells were investigated for 
feasibility of employing PPF in practical applications. First, we demonstrated the fabrication of 
MCs with diameters of 120 – 510 μm by crosslinking core/shell microdrops of highly viscous 
alginate solutions generated from a coaxial nozzle at a rate of 1,000 drops/sec. Controllability of 
the microdrop size was validated, optimizing the cell confinement in the core. As practical 
applications, NIH 3T3 fibroblasts or human and pig islets were encapsulated by PPF, exhibiting 
no cell protrusion or decrease in their viability.  
Uniform core/shell MCs co-encapsulating poly (ε-caprolactone) MSs with NIH 3T3 
fibroblasts as model anchorage dependent cells (ADCs) were designed to increase the survival of 
the cells via re-establishment of cell-substrate interactions. The core/shell MCs with the altered 
intracapsular environment resulted in higher cell survival and proliferation when compared to 
those without the MSs or the alginate/poly-L-lysine/alginate MCs. This study provides a proof of 
concept of the co-encapsulation of microspheres with therapeutic ADCs. 
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In order to apply such co-encapsulation strategy to islet xenotransplantation for the 
treatment of type 1 diabetes, we encapsulated porcine islets together with exenatide-loaded 
poly(latic-co-glycolic acid) MSs to enhance islet survival and function as exenatide locally 
released in the intracapsular environment. The MCs with exenatide-loaded MSs showed improved 
glucose-stimulated response. The results indicate that the co-encapsulation concept of exenatide-
loaded MSs with porcine islets is a promising strategy for achieving long-term survivability and 
function of islets, while overcoming donor shortage by reducing the required transplanted islet 
mass. 
Microencapsulation and controlled release of Pantoea agglomerans strain E325 (E325), an 
antagonist to the bacterial plant pathogen Erwinia amylovora that causes fire blight, a devastating 
disease of apple and pear, have been investigated. To preserve viability and promote proliferation, 
E325 was encapsulated with nutrients in core/shell MCs. Controlled release of E325 was achieved 
by separately adjusting alginate concentrations in the shell and core solutions, and by controlling 
the MC size. Proliferation of E325 within MCs, followed by their subsequent release, and 
colonization activities on apple flowers were investigated. This study could serve as a model for 
further studies on development of effective plant disease management strategies. 
Next, we focused on the feasibility of the MC-mediated treatment for field applications 
exposed to rapid and wide fluctuations in moisture and nutrient levels and storability of the 
inoculum. This study demonstrated the following advantages: (1) maintenance of E325 viability 
in moisture-poor environments including hypanthium, the most common site of infection, (2) 
improved suppressive activity against the pathogen of fire blight (strain Ea153) at various relative 
humidity, and (3) long-term survivability through lyoprotection and osmoadaptation. 
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CHAPTER 1  
INTRODUCTION 
 
1.1. Background  
Recent advances in biotechnology have allowed for the development of new classes of 
highly effective therapeutic agents such as drugs, proteins, genes, and cells. Their therapeutic 
efficacies can be improved through employing drug delivery systems (DDS) such as microcapsules 
(MCs) and -spheres (MSs) [1]. DDS is designed to deliver the therapeutic agents in the required 
dose, at the right time, to the diseased or damaged site in biological systems. Cell delivery system 
is based on the concept of cell microencapsulation where therapeutically active cells are 
immobilized within a polymer matrix surrounded by semipermeable membrane, protecting the 
encapsulated cells against external mechanical stress during delivery and the host immune system, 
while allowing the influx of the essential molecules for cell metabolism, such as nutrients, oxygen, 
and metabolic products, and the outflow of waste and therapeutic products. This idea of 
encapsulating therapeutic cells, originally proposed for medical purposes, has expanded its 
applications into pharmaceuticals, food industries, and agriculture through a number of 
encapsulation strategies [2-6]. Compared to fabrication of microspheres containing non-living 
agents, cell encapsulation fundamentally has different natures in manufacturing the products 
because cell viability and function should be maintained during the encapsulation processes. A 
number of refinements to the technique have been proposed over the years to improve generation 
of the required microcapsules and the intracapsular microenvironment [7-9]. However, various 
methods for producing therapeutic microcapsules for cell transplantation have not met the 
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requirements for practical significance [3, 10-13]. This failure stems from the shortcomings of the 
conventional microdrop generation methods in facing the technical challenges for practical 
applications, which include (1) high reproducibility and controllability of capsule parameters, such 
as size, size uniformity, sphericity, and permeability, (2) handling of polymer solutions of high 
viscosity, (3) prevention of cell protrusion to suppress elicitation of immune reactions, and (4) 
high throughput to shorten the intervening period between patient hospitalization and 
transplantation. 
Microsphere-mediated DDS is one of the most common forms of DDS for containing non-
living agents due to injectable administration, high reproducibility, and flexibility for hydrophilic 
and hydrophobic drugs [14].  Following are the requirements for successful applications: (1) 
acceptable biocompatibility (non-toxicity and non-immunogenicity) and minimized side effects; 
(2) biodegradability at the desirable rate during required time period; (3) ideal mechanical property 
to shield the therapeutic agents from damage by compressive or tensile forces without inhibiting 
appropriate biomechanical cues; (4) maintenance of drug levels in a desirable range; (5) low cost, 
high throughput, and precise control in particle fabrication; (6) longer in vivo half-lives of drugs 
for delivery; and (7) minimizing the number of dosages for patients’ convenience [15, 16]. A 
number of materials have been exhaustively explored to enhance drug safety and efficacy which 
can be divided into two main categories: synthetic polymers such as poly(ε-caprolactone) [17, 18], 
poly (lactic-co-glycolic acid) [19-21], poly(ethylene glycol) [22, 23], poly(vinyl alcohol) [24, 25], 
and poloxamer [26, 27], and natural polymers including alginate [28, 29], chitosan [25, 30, 31], 
gelatin [32, 33], collagen [34, 35], and starch [36, 37]. Choosing a suitable material is one of the 
most important strategies in various DDS applications.  
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Microcapsule- and microspheres-mediated DDS has been developed with a variety of 
methods such as emulsion, precipitation, and spray drying [30, 38-42]. Although these methods 
have different capabilities in the achievable size range, uniformity, and production rate of spheres 
and loading efficiency and limited flexibility in drugs, there are common features in parts. For 
example, polymers and drugs should be dissolved in suitable organic solvents or drugs could be 
suspended as solid particles, and then emulsified in another solvent, immiscible with the organic 
solvents. In drug-polymer emulsion, droplets are generated and subsequently solidified according 
to each fabrication method. Of these methods, emulsion is the most commonly used, especially for 
fabrication of nanospheres. This method is based on oil-in-water (o/w) emulsification of solutions 
containing the polymer and drug in non-solvent phase with a stabilizer. Although this is a relatively 
simple and easy process, the following disadvantages have limited its application: difficulty of 
scale-up, high cost at large-scale production, wide size distribution of the resulting spheres, and 
poor loading efficiencies of water-soluble drugs. Fabrication of spheres with narrow size 
distribution is important because their size directly affects the drug release rate and syringability. 
The precipitation (or coacervation) method consists of phase separation of polymer solution into 
droplets in organic solutions containing the drug and entrapment of the drug by addition of a third 
component to the polymer solution [43, 44]. This process, unlike the emulsion method, allows 
entrapping both hydrophilic and hydrophobic drugs as a non-aqueous method. However, the 
coacervate droplets are frequently agglomerated due to absence of any emulsion stabilizer and the 
resulting size distribution is typically broad [44]. For spray drying, an atomizer generates droplets 
of the polymer-drug mixture, thereby extracting the solvent by a carrier stream of hot air. The 
diameter and size distribution of spheres are determined on the atomization stage. The spray drying 
method is rapid, convenient, easy to scale-up, and less dependent on the solubility of drugs and 
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polymers used. Also, the resulting size distribution is relatively narrow compared to the above two 
methods. But, the high temperature and shear force of the solvent-extracting air could damage the 
therapeutic agents entrapped in the spheres. Moreover, using air flow could lead to not only a 
significant loss of spheres by adhesion to the inside wall of the drying chamber and agglomeration 
during spray-drying, but also non-sphericity of the resulting particles [45]. Although a number of 
microcapsule and sphere fabrication techniques have been improved, they have not fully met the 
requirements as mentioned in the previous section. Particularly, since microsphere size and 
uniformity are critical deciding factors of the drug release rates, it has been required to develop a 
methodology for controlling the release kinetics by employing size-controlled uniform 
microspheres. However, none of the conventional methods has enabled successful fabrication of 
spheres in the size range needed for drug delivery applications while achieving narrow size 
distribution. In this thesis work, the precision particle fabrication (PPF) method, originally 
developed by Professor Kevin Kim [46-66], is of particular significance and interest, which has 
allowed the fabrication of uniform microspheres and core/shell microcapsules with precisely 
controlled sizes that are capable of efficiently encapsulating drugs and even living cells. The PPF 
method has been evolved enabling fabrication of uniform microcapsules of controlled size and 
shell thickness in a single-step process. Precise control of the volumetric flow-rates of the core and 
shell fluids allows custom-tailored core/shell structures. For clinical significance of the controlled 
release systems, the monodisperse microspheres and core/shell microcapsules fabricated by the 
PPF method offer advantages in reproducibility, control, flexibility, and most importantly, relative 
insensitivity to the choice of materials, providing valuable assistance and flexibility in designing 
advanced drug delivery systems.  
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1.2. PPF Method 
The PPF method can fabricate uniform microspheres and microcapsules of controlled sizes 
and core/shell structures with a variety of natural and synthetic polymers using acoustic excitation. 
In this method, acoustic streaming is used to achieve predefined sphere size and narrow size 
distribution. Acoustic streaming, defined as a fluid flowing in a certain constricted channel (such 
as a nozzle) acted upon by an acoustic wave, is a well-known phenomenon. This, for example, is 
achieved by launching an acoustically excited pressure along a liquid jet. The uniform drop 
formation resulting from the instability of an inviscid liquid jet emerging through a circular orifice 
under a controlled pressure modulation (i.e., an acoustic excitation) into the atmosphere was noted 
as early as 1833 by Savart [67] and described mathematically by Lord Rayleigh [68]. This 
generation process of monodisperse drops has had a great practical importance in ink-jet printing, 
fuel injection, particle sorting, and atomization, to name a few examples [69, 70]. Furthermore, 
the control of droplet size and its distribution is very useful and critical for new applications 
including drug delivery systems. 
To generate uniform microdrops, the employed polymer solutions were provided through 
a coaxial nozzle forming a liquid jet, in the form of a cylindrical column, and broken into uniform 
drops by introducing acoustic excitation (mechanical force), allowing to choose the wavelength λ 
= vj / f  by adjusting the acoustic frequency f and the linear velocity of the liquid jet vj. The total 
initial mass of the last cycle of the liquid jet is used to form the droplet of radius rd formed when 
the constriction ruptures. Here the mass balance is written as  
ݎௗ = (3ݎ௝ଶݒ௝  / 4݂)ଵ/ଷ           
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Based on Rayleigh’s result [68], the radius, rd,max, of the drops formed is 1.891 rj at the 
optimum wavelength. Therefore, a uniform and high-amplitude oscillation imposed on the nozzle 
can control the liquid jets, which depends on the orifice size rj, stream flow velocity vj, set 
frequency f, and set amplitude A. However, the smallest drop size achievable is approximately 
twice the orifice diameter. Any further reduction of drop size requires a smaller orifice, which is 
not applicable to highly viscous solution because shear forces at the orifice and the potential for 
clogging increase. A most remarkable aspect of the PPF technology is that it is capable of 
fabricating uniform and double-walled microspheres exhibiting controllable size and shell 
thickness, offering a number of significant advantages, such as programmable (scheduled) drug 
delivery, efficient drug usage, higher drug loading, and improved drug stability [55]. Precisely 
defined drop size distributions can be achieved with the desired shell thickness for the core/shell 
microcapsules. In addition, by employing different materials for the core and shell domains, one 
can generate a variety of synergetic effects from the core/shell microspheres inserted in the target 
drug-delivery site.  
 
1.3. Overview 
This thesis study provides the feasibility of PPF for application of microcapsules and 
microspheres for medical and biological purposes. To overcome the limitations of existing cell 
encapsulation processes for clinical applications, we primarily demonstrated the following 
capabilities of PPF technology for cell encapsulation: (1) precise control of capsule size; (2) 
sphericity and uniformity; (3) handling of high-viscosity solution; (4) prevention of cell protrusion; 
(5) high throughput; and (6) maintaining cell viability. Furthermore, we optimized the fabrication 
conditions of core/shell microcapsules with various cell sources, such as animal cell line (NIH/3T3 
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fibroblasts) and human and pig islets, for the feasibility of employing PPF for practical applications 
involving cell delivery system. 
As a novel capsule system, we fabricated semi-liquid core/shell microcapsules 
encapsulating animal cells with cell-friendly mini-microspheres that serve as anchors to induce re-
establishment of appropriate cell-cell and cell-matrix substrate interactions. The viability and 
proliferation of the cells encapsulated in these capsules were compared with that of the cells 
encapsulated in alginate capsules without microspheres as well as those with poly L-lysine and 
alginate coating, the most studied capsule concepts. Prior to encapsulation, we fabricated 
monodisperse poly (ε-caprolactone) microspheres of various sizes, optimized the size and 
concentration of the microspheres appropriate to be encapsulated in the capsule core, and evaluated 
adhesion of NIH 3T3 fibroblasts to the microsphere surface.  
As an islet xenotransplantation system for treatment of type 1 diabetes, we designed 
alginate microcapsule system co-encapsulating porcine islets with exenatide-loaded poly(latic-co-
glycolic acid) (PLGA) microspheres that serve as microdepots to locally deliver exenatide to the 
encapsulated islets. Monodisperse exenatide-loaded PLGA MSs at various loadings were 
fabricated by the PPF method and their release characteristics were investigated to determine the 
optimal dosage. The viability and glucose-stimulated insulin secretion (GSIS) of the islets 
encapsulated in the capsules were compared with that of the islets encapsulated in alginate capsules 
without exenatide-loaded PLGA MSs.   
As another biological application, the encapsulation method served as a delivery model of 
therapeutic bacterial cells for the development of effective plant disease management strategies. 
Microencapsulation and controlled release of the biocontrol agent Pantoea agglomerans strain 
E325 (E325), an antagonist to the bacterial plant pathogen Erwinia amylovora that causes fire 
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blight, a devastating disease of apple and pear, have been investigated. The bacterial cells E325 
were encapsulated within the core, along with nutrients, of microcapsules of precisely controlled 
sizes. Controlled release of E325 from microcapsules and its viability were investigated at various 
temperatures. Furthermore, post release migration of E325 on stigmatic tissues of apple flowers 
toward the hypanthium was monitored to provide a proof of concept of the successful use of 
microencapsulated biocontrol agents.  
As an extended work, we have investigated the feasibility of the microcapsules-mediated 
treatment for field applications exposed to rapid and wide fluctuations in moisture and nutrient 
levels and storability of the microcapsule product. At various relative humidities, we investigated 
the effectiveness of the alginate microcapsule (AMC)-meditated strategy regarding whether its 
water retentivity can contribute to survivability of E325 in a moisture-poor environment, allow 
continuous release of large population sizes of E325, and maintain its suppressive activity against 
the pathogen of fire blight (strain Ea153) on floral surfaces. Furthermore, for practical field 
application of microcapsule-mediated biocontrol, the efficacy of encapsulation in the presence of 
lyoprotective agents was assessed on the survivability and preparation stability of encapsulated 
E325 during freeze-drying and storage. 
This dissertation is organized as follows. From Chapter 2 to Chapter 6, various biological 
applications of microsphere/microcapsules fabricated by the PPF method are presented. Chapter 2 
describes advantages of the PPF method in cell encapsulation. Then, an advanced cell 
encapsulation strategy is presented in Chapter 3, and its specific application for treatment of 
diabetes is discussed in Chapter 4. Chapter 5 and 6 provide a proof of concept of the successful 
use of microencapsulated antagonists against the pathogen of fire blight disease. Finally, 
concluding remarks and discussion of future work are provided in Chapter 7. 
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CHAPTER 2  
ENCAPSULATION OF LIVING ANIMAL CELLS USING 
PPF METHOD  
 
2.1. Introduction 
Although surgical therapy consisting of reconstruction surgery and organ transplantation 
has been undoubtedly the savior of countless lives, it has several limitations such as progressive 
deterioration of damaged tissues and organs, growing supply-and-demand mismatch of donor 
tissues or organs, continuous and permanent use of immunosuppressive agents for prevention of 
immunological rejection responses, and risk of bacterial and viral infection and carcinogenesis 
[71]. To overcome these issues in surgical therapy and further accelerate the regeneration and 
repair of the defective and damaged tissues in patients’ bodies, new therapeutic strategies have 
been required. In this clinical situation, cell-based therapies have emerged as a major modality in 
regenerative medicine. This treatment modality is intended to naturally heal the diseases by 
successful delivery of living cells to the sites of degeneration where the cells can exert therapeutic 
effects to repair damaged tissues/organs or eliminate malignant neoplasms. Cell-based therapy is 
categorized to three approaches: cell transplantation, tissue engineering, and cell-based drug 
delivery (Figure 2.1). Cell transplantation is an autograft based on cells highly qualified in 
proliferation, differentiation, and function to induce tissue regeneration by injection or infusion 
method. However, the approach results in low therapeutic efficacy because the cells are hardly 
accumulated and grafted at the transplanted site to be regenerated. To overcome the problem, it is 
necessary to provide the cells the suitable environment, termed a ‘scaffold’, for effective 
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accomplishment of their missions such as adherence, proliferation, and differentiation [72]. Then, 
the cells synthesize matrices of new tissue as well as function on behalf of the diseased or damaged 
tissues. This approach is called tissue engineering and was originally proposed by Langer and 
Vacanti [73]. As another strategy, cell-based drug delivery has been regarded as a more practical 
alternative to repair damaged tissues or eliminate neoplasms, especially for patients suffering from 
chronic diseases such as diabetes and Parkinson’s disease [74, 75]. Here the cells act as drug depots 
enabling the delivery of therapeutic molecules over an extended time period.  
Encapsulation of therapeutically active cells in semipermeable microcapsules is a several-
decades-old concept [76]. This has been regarded as a promising strategy to suppress immune 
response by use of allogenic or xenogenic cell sources and to increase the efficacy and viability of 
transplanted cells while protecting them against external mechanical stress and providing a 
structure similar to extracellular matrices (ECM), while allowing the influx of the essential 
molecules for cell metabolism, such as nutrients, oxygen, and metabolic products, and the outflow 
of waste products and therapeutic proteins (Figure 2.1). The idea of encapsulating living cells 
subsequently led to the development of a number of encapsulation technologies for applications in 
the pharmaceutical, chemical and food industries, as well as in agriculture, biotechnology, and 
medicine [2, 3, 10, 13, 77, 78].  
We primarily attempted to overcome the limitations of existing encapsulation processes in 
order to move towards practical clinical applications. The present study demonstrates the following 
capabilities of the cell encapsulation method, derived from the PPF method: (1) size controllability; 
(2) sphericity and uniformity; (3) acceptability of high-viscosity solution; (4) safe confinement of 
cells (no protrusion); (5) high throughput; and (6) no or minimal damage during encapsulating 
cells. We encapsulated various cell sources such as animal cell line (NIH 3T3 fibroblasts) and 
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human and pig islets in core/shell structured microcapsules by use of a dual co-axial nozzle and 
assessed their viability. Especially, encapsulation of pig islets holds great promise for large-scale 
application of islet transplantation. The recent achievements of porcine islet xenotransplantation 
in type 1 diabetes patients provide further rationale for islet replacement as an alternative 
therapeutic option, since the limited human islet supply and poor islet yield and quality have 
remained substantial obstacles in the field and xenogeneic islets isolated from pig pancreas can be 
provided limitlessly while being protected against the host’s immune system as they are 
immobilized within the capsule [79, 80].  
 
2.2. Materials and Methods 
2.2.1. Materials 
Protanal® SF 120 (FMC BioPolymer, Drammen, Norway, MW = 237 kDa, FG = 0.694) 
was donated by Prof. Skjåk-Bræk. Alginic acid sodium salt (MW = 9.5 kDa) [81], Tween 20, 3-
(N-morpholino)-propane-sulfonic acid (MOPS), and BaCl2 were purchased from Sigma-Aldrich 
(Milwaukee, WI, USA), CaCl2 Fluka (USA), and mannitol VWR (USA), and used without further 
purification. 
2.2.2. Cell Sources and Culture Conditions 
2.2.2.1. Cell line 
Fibroblast cell line NIH 3T3 was purchased from American Type Culture Collection 
(ATCC, USA) and routinely sub-cultured as a monolayer in Dulbecco’s modiﬁed Eagle's medium 
(DMEM, Mediatech Inc., USA), supplemented with heat-activated fetal bovine serum (10% v/v) 
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(FBS, Hyclone Lab. Inc., USA), penicillin (100 IU/ml) and streptomycin (100 μg/ml) (Pen/Strep) 
in a humidified incubator with 5% CO2 in air at 37 °C.   
2.2.2.2. Human islets  
Human islets were received from the Cell Isolation Laboratory, University of Illinois at 
Chicago, and cultured in CMRL-1066 media (Mediatech, Herndon, VA), supplemented with 1.5 % 
human albumin, 0.1 % insulin-transferrin-selenium (ITS), and Pen/Strep at 37°C in 5% CO2.  
2.2.2.3. Pig Islet Isolation  
Islet isolation was performed by modification of the pancreatic ductal perfusion technique 
[82]. Pancreas was obtained from male pigs at 5 to 6 months old (Department of Animal Science, 
University of Illinois). The pancreas was transported to the laboratory in cold (4°C) Hanks’ 
solution containing 10% FBS. The ischemia time at the slaughterhouse was 10–15 min and the 
pancreas remained in the cold Hanks’ solution for 20 min before the islet isolation procedure was 
initiated. Only the splenic lobe of pig pancreas was used for islet isolation. The pancreatic duct 
from duodenal lobe to the splenic lobe was cannulated by transverse dissection and inserting 20 to 
22 gauge plastic catheters passed into both branches of the main duct. All major vessels supplying 
the pancreas were clamped and the pancreas prepared for perfusion through the plastic cannula. 
200 ml of collagenase (1mg/ml in Hanks’ solution with 10% FBS, Sigma, St. Louis, MO) was 
slowly injected into the pancreatic duct. The pancreas distended easily, and some portion of 
collagenase solution accumulated under the serous membranes on the surface of the pancreas. 
Adherent lymph nodes, blood vessels, and fat tissue fragments were carefully removed during the 
perfusion process. The pancreas was transferred to a petri dish containing collagenase solution and 
then minced with scissors under sterile conditions. The resulting pieces were incubated at 37°C 
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for 10–15 min. Digestion was stopped by placing the pancreas in Hank’s solution containing 10% 
FBS. The digested pieces were filtered through a stack of three sterile meshes (1.18 mm in the 
uppermost, 0.71 mm in the next, and 0.595 mm in the bottom in mesh size) and washed through 
the meshes with cold Hanks’ solution with 10% FBS. The tissue filtrate was separately transferred 
to a 50 ml centrifuge tube to allow settling by gravity to the bottom of the tube at 2000 rpm for 5 
minutes at 4°C. The supernatant from each tube was aspirated, and subsequently the resulting 
pellet was delicately resuspended in 50 ml of fresh Hanks’ solution with 10% FBS at 1500 rpm 
for 1 min at 4°C. This washing step was repeated once more. Afterward, the pellet was gently 
resuspended in 6 ml 25% (w/v) Ficoll and carefully layered in the tubes by succeeding layers of 
23, 20.5, and 11% (w/v) Ficoll (each 4 ml). The tubes were centrifuged at 2500 rpm for 10 min at 
4°C. The largest number of islets was usually present in the first layer. The layers were collected 
individually with a Pasteur pipette and washed by centrifugation with Hanks’ solution with 10% 
FBS at 2500 rpm for 15min at 4°C. The islets was resuspended in RPMI-1640 containing 2 mML-
glutamine, 10% FBS, and Pen/Strep for incubation at 37°C in 5% CO2. The islet particle number 
(IPN) and islet equivalent (IEQ) were in a range of 25,500 to 84,000 and 43,000 to 124,000, 
respectively. 
2.2.3. Microencapsulation 
The applied microcapsule chemistry was previously described by Skjåk-Bræk’s group [83, 
84]. Briefly, NIH 3T3 fibroblasts were trypsinized and then centrifuged at 3,000 rpm for 5 min at 
room temperature. The media was decanted and the cells were re-suspended in alginate solution 
(in 0.3M mannitol, pH 7.2-7.4). For human and pig islets, the islet suspension was centrifuged at 
1,000 rpm for 2 min, room temperature, and, after removing the supernatant, the islets were 
resuspended in a small volume of each culture medium. The islet suspension was mixed with a 
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sterile filtered alginate solution (in 0.3M mannitol, pH 7.2-7.4) to a final suspension of 2,000 IE/ml 
in alginate solution.  
Cell encapsulation was performed by modifying the PPF method. Briefly, sodium alginate 
was dissolved in dH2O to prepare solutions of 1 – 2.5 w/v % in 0.3 M mannitol, pH 7.2 – 7.4; 
polymer concentrations are indicated as appropriate in Section 2.3. In some cases, natural oil was 
used to show the difference as the flow rate decreases and trypan blue was co-dissolved in the 
alginate solution to aid in visualization of the two phases. The alginate solutions were provided to 
the dual coaxial nozzle through separate syringe pumps at respective flow rates ranging from 1.0 
to 15.0 ml/mn. A dual coaxial nozzle was used to produce a jet of an inner core-forming steam 
surrounded by an outer stream containing solutions of different condition or polymer. The core-
shell polymer jet was broken up into uniform droplets by acoustic excitation of the nozzle, and 
collected in the stirred bath of the gelling solution (50 mM CaCl2 and 1 mM BaCl2 in 10 mM 
MOPS, 0.14 M mannitol and 0.05% Tween 20, pH 7.2-7.4). The alginate microcapsules in the 
gelling solution were collected on a filter and then washed three times before being transferred to 
Petri dishes for culturing at 37 oC and 5% CO2. 
2.2.4. Characterization 
The morphologies of the microdrops and microcapsules of core-shell structure were 
observed and characterized by a CCD camera and an optical microscope (Olympus BX41, 
Olympus America Inc., USA) in the bright field, respectively. The capsule size was measured from 
the optical images of the alginate microcapsules. 300 microcapsules were sampled to obtain the 
size distribution. The viscosity of 1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 wt.% aqueous alginate solutions 
in 0.3M mannitol was measured using a digital rotational viscometer Brookfield DV-II+ 
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(Brookfield Engineering Labs., Inc., Middleboro, MA, USA) (Table 2.1). The recording of the 
viscometer output parameters started 2 min after the experiment onset. The changes of η and torque 
were monitored at 20 ± 0.1 °C by the spindle rotational speeds of 3 – 60 rpm. 
2.2.5. Cell Viability 
Viability of encapsulated and non-encapsulated cells and islets was assessed by the 
fluorescence microscopy (Olympus IX81, Olympus America Inc., USA) by staining them with 
SYTO- Green/Ethidium Bromide (EB) [85]. Briefly, stock solutions of SYTO-green (5 mM in 
DMSO) and EB (10 mg/ml) were stored at -20oC and room temperature, separately. The working 
solution was freshly prepared before assay [83]. Microcapsules were washed with pre-warmed 
Hank’s balanced salt solution (HBSS) and re-suspended in 2ml of HBSS. To this, 200 μl of SYTO-
green solution was added, followed by the addition of 100 µl of EB solution.  
 
2.3. Results and Discussion 
We employed the alginate hydrogel as a 3D structure-forming material, which is the most 
widely used and characterized biomaterial for cell encapsulation. To generate core/shell drops, 
alginate solutions were fed through the inner and outer regions of a coaxial nozzle as shown in 
Figure 2.2. The resulting coaxial jet streams were subsequently broken up into a train of uniform 
core/shell drops by acoustic excitation at a rate of > 1,000 drops/sec. Flow rates of the two coaxial 
jet streams were varied to control the aspect ratio and size of the core/shell droplets, which were 
collected and cross-linked with the Ca2+ and Ba2+ ions in a gelling bath. The optical micrographs 
in Figure 2.3(a)–(e) show thus-produced alginate microcapsules of sizes in the range of 100 – 500 
μm in diameter, demonstrating the size uniformity and controllability. The capability to precisely 
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control the capsule size is crucial since materials transport to and from the encapsulated cells relies 
mainly on diffusion [84, 86]. For instance, in islet encapsulation, efforts have been focused on 
reducing the capsule size not only to minimize the graft volume but also to facilitate oxygen 
transport to the encapsulated islets since the surface-to-volume ratio decreases with the capsule 
size.  In fact, hypoxic loss of islets is one of the main causes of the failure of encapsulated islets 
following transplantation [87]. Unfortunately, conventional methods have problems in reducing 
the drop size of high-viscous hydrogel materials to produce uniform-sized microcapsules of sizes 
of < 500 μm in diameter [10, 88]. Figure 2.3(f) shows a CCD (charge-coupled device) image of an 
alginate droplet with the core including trypan blue, revealing distinct regions of core and shell 
without intermixing. This indicates that the cells, fed with the inner solution, would be confined 
in the core region of the droplet, preventing cell protrusion, while crosslinking of the alginate 
molecules takes place as the Ca2+ and Ba2+ ions diffuse into the droplet. The confinement of the 
cells in the core could be further optimized by adjusting the aspect ratio of the core/shell drops. 
We investigated this effect on the aspect ratio of the alginate drops employing an oil core, 
so that the interface between the core and shell could be maintained with no mixing after gelation. 
Figure 2.4 shows the optical images of the alginate microcapsules prepared by feeding canola oil 
through the inner nozzle. In this sequence of experiments, the outer (shell) solution flow rate was 
fixed at 12 ml/hr while the inner (core) solution feed rate was incrementally adjusted to 3, 2, 1, 
and 0.5 ml/hr, respectively, to produce  microcapsules with decreasing core size and increasing 
shell thickness. The controllability of shell thickness demonstrated here would offer an additional 
edge for confining cells in the capsule core to prevent them from protrusion.  
Biocompatibility of alginate capsule is associated with its mechanical stability and 
elasticity as well as permeability, which are related to the viscosity of the alginate material, 
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governed by its molecular weight and solution concentration [3, 89]. Eventually, highly viscous 
alginate solutions are required to fabricate biocompatible alginate microcapsules for clinical 
applications, rendering the process of generating uniform alginate microdrops extremely 
challenging. We investigated the encapsulation of NIH 3T3 fibroblasts and human islets using the 
Protanal® SF120 alginate. The microdrops encapsulating the fibroblasts were generated by feeding 
the alginate solutions of 1.5 and 2.5% (w/v) in concentration into the inner and outer nozzles of 
the capsule fabrication system, respectively, and cross-linked in the collection bath containing 
CaCl2 and BaCl2. The optical and fluorescence images in Figure 2.5 indicate that the resulting 
microcapsules were spherical and uniform in size, from which no cell protrusion was detected. 
The cells were observed to be mobile inside the capsule, suggesting that the crosslinking was 
inhomogeneous across the drop. This could be attributed to the migration of the alginate molecules 
toward the surface during the crosslinking process, lowering the crosslinking density in the core 
region, which was magnified by the low concentration of the inner solution. The latter might also 
have facilitated the confinement of the cells in the core during the process of drop formation. The 
cell viability assessed by the SYTO-green and EB staining manifested no significant decrease after 
encapsulation. The optical and fluorescence images taken at 1 and 3 days after encapsulation show 
the cells were growing inside the capsule. The cell growth might have been promoted by the soft 
core, which would ease the cell movement to form clusters. Human islets were encapsulated in the 
same manner as the NIH 3T3 fibroblasts except for the concentration of the outer solution, which 
was 2.8 w/v %. Figure 2.6(a) shows the optical and fluorescence images of the human islets before 
and after encapsulation. The capsules were spherical and uniform in size, exhibiting no cell 
protrusion, offering an important advantage for clinical applications. The average size of the islet 
encapsulating capsules was 560 ± 20 µm in diameter, validating the size uniformity of the capsules 
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(Figure 2.6(b)). The SYTO-green and EB staining manifested no significant decrease in the cell 
viability after encapsulation.  
Furthermore, to assess the feasibility of the present encapsulation method to islet 
xenotransplantation, islets were isolated from pigs and subsequently encapsulated by feeding the 
alginate solutions of 1.0 and 2.0% (w/v) in concentration into the inner and outer nozzles, 
respectively (Figure 2.7). The result was similar to what was observed in human islets 
encapsulation and the SYTO/EB staining in which, after encapsulation, there was no significant 
decrease in viability.  
 
2.4. Conclusion 
In this study, we demonstrated the fabrication of microcapsules with diameters of 120 – 510 
μm by crosslinking core-shell microdrops of highly viscous alginate solutions generated from a 
coaxial nozzle at a rate of 1,000 drops/sec. In addition, we validated the controllability of the aspect 
ratio of the microdrops, which would optimize the cell confinement in the core. As a result, the 
NIH 3T3 fibroblasts or human and pig islets encapsulated by this method exhibited no protrusion. 
The as-encapsulated cells showed no decrease in their viability. Therefore, the present 
encapsulation method could fulfill important prerequisites for clinical applications of cell 
encapsulation.  
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2.5. Table and Figures 
Table 2.1 Viscosity vs concentration of alginates in 0.3M mannitol, 20oC 
Alginate Conc. (% w/v) 1.0 1.5 2.0 2.5 2.8 3.0 3.5 
Sigma Viscosity (cps) 24 53 214 280 . 561 957 
SF120 Viscosity (cps) N 190 321 581 989 . . 
* Sigma alginate: Mw 9.5K, FG 0.51 [81] * SF120 alginate: Mw 237K, FG 0.694 (provided FMC Biopolymer, Drammen, Norway) 
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 Figure 2.1 A schematic of cell encapsulation (top) and optical micrograph of alginate microcapsule encapsulating NIH 3T3 fibroblasts (bottom).  
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Figure 2.2 A schematic of the PPF set-up for cell encapsulation. 
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Figure 2.3 Optical micrographs of the alginate microcapsules with diameters of (a) 120±10, (b) 220±10, (c) 330±10, (d) 400±10, and (e) 510±10 μm, fabricated by the PPF method. Scale bar = 500 μm. (f) A charge coupled device image of an alginate solution drop with a trypan blue-stained alginate core. Scale bar = 200 μm. 
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Figure 2.4 Optical micrographs of alginate microcapsules with oil core with decreasing core size as the core stream flow rate  decreased to (a) 3, (b) 2, (c) 1, and (d) 0.5 ml/hr while the outer shell solution was fixed at 12 ml/hr. Scale bar = 500 μm.   
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Figure 2.5 Optical (first column) and fluorescence (second column) micrographs of as-encapsulated NIH 3T3 fibroblasts (first layer), 1 day (second layer), and 3 days (third layer) after encapsulation. Cell viability was determined by SYTO-green and ethidium bromide (EB) staining after the encapsulation process: SYTO- (green) and EB-stained islets (red). 
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Figure 2.6 (a) Optical and fluorescence micrographs of non-encapsulated human islets as a control (first column) and encapsulated human islets after encapsulation (second column) and at 1 day (third column). Scale bar = 500 μm. Viability of human islets was determined by SYTO-green and EB after the encapsulation process: SYTO- (green) and EB-stained islets (red). (b) Size distribution of alginate microcapsules encapsulating human islets. The insert shows an optical image of a typical alginate capsule encapsulating islets. Scale bar = 200 μm. 
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Figure 2.7 (a) Optical micrographs of islets isolated from pig pancreas. Scale bar = 200 (left) and 500 μm (right). (b) Optical and fluorescence micrographs of non-encapsulated pig islets as a control (top layer) and encapsulated porcine islets after encapsulation (bottom layer). Scale bar = 500 μm. Viability of porcine islets was determined by SYTO-green and EB after the encapsulation process: SYTO- (green) and EB-stained islets (red). 
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CHAPTER 3 
CO-ENCAPSULATION OF ANCHORAGE DEPENDENT 
CELLS WITH CELL-FRIENDLY MICROSPHERES TO 
INDUCE CELL-SUBSTRATE INTERACTIONS IN CORE-
SHELL MICROCAPSULES  
 
3.1. Introduction 
Cell microencapsulation is intended to treat diseases by delivering living cells to the sites 
of degeneration where the cells can exert therapeutic effects to repair/regenerate damaged tissues 
or eliminate malignant neoplasms, while allowing immunoisolation [76, 90]. Alginate hydrogels 
have been extensively used for cell encapsulation studies [3, 91]. However, cells entrapped in 
alginate matrices are confined to a round shape regardless of their native morphology, as the 
hydrogels promote minimal protein adsorption [92-94]. Various strategic concepts have been 
proposed to increase the survival and functions of therapeutic cells, which include the alteration 
of the intracapsular environment [95-98]. Capsules with a semi-liquid core emerged as a 
compromise. In any case, unlike the native microenvironment rich in extracellular matrix (ECM) 
components, the intracapsular microenvironment of alginate capsules is inert, limiting cell 
adhesion and interactions. This could be beneficial for the chondrogenic differentiation of native 
cartilage cells, enhanced by the formation of spheroidal cell aggregates rather than outstretched 
cells that lead to dedifferentiation. However, in the case of osteoblasts, anchorage-dependent cells 
(ADCs), which require cell spreading via cell-substrate interactions to maintain their normal 
phenotype, osteogenesis or other morphogenesis could be scarcely achieved on highly hydrophilic 
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surfaces [99, 100]. Anchorage dependence is especially important for long-term survival of 
therapeutic ADCs, such as stem cells, progenitor cells and lineage-committed cells, in performing 
cellular missions including migration, proliferation, differentiation and apoptosis [101-105]. 
Therefore, appropriate establishment of cell-substrate interactions would be a promising strategy 
for long-term survival and function of therapeutic ADCs. 
In this study, we prepared alginate (AL) microcapsules with a semi-liquid core, 
encapsulating ADCs together with or without poly (ε-caprolactone) (PCL) microspheres. The cell 
viability and growth in these capsules were compared with those in liquid-cored AL capsules, 
coated with poly L-lysine (PLL) and AL, encapsulating no PCL microspheres [76, 88]. NIH 3T3 
fibroblasts, which are anchorage-dependent, were used as a model therapeutic ADC. PCL is a 
biodegradable polyester, which is widely used for tissue engineering and drug delivery [106]. Prior 
to encapsulation, we fabricated monodisperse PCL microspheres, evaluated cell adhesion to the 
sphere surface, and determined an appropriate sphere concentration to be encapsulated in the 
capsule core. 
 
3.2. Materials and Methods 
3.2.1. Materials 
Poly(ε-caprolactone) (PCL, Mw 43,000~50,000) and 80% hydrolyzed poly(vinyl alcohol) 
(PVA, MW ~6,000) were purchased from Polysciences, Inc. (Warrington, PA, USA). HPLC- 
grade dichloromethane (DCM) was purchased from Fisher Scientific. Alginic acid sodium salt 
(MW 60,000~70,000), agarose, Tween 20, mannitol, CaCl2, and BaCl2 were purchased from 
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Sigma-Aldrich (St. Louis, MO, USA). AL solutions were filtered through cellulose acetate 
membranes with pore sizes of 0.8, 0.45, and 0.22 μm, consecutively. All chemicals were used 
without further purification.  
3.2.2. Cell Line and Culture Condition 
Fibroblast cell line NIH 3T3 was purchased from American Type Culture Collection 
(ATCC, USA) and routinely sub-cultured as a monolayer in Dulbecco’s modiﬁed Eagle's medium 
(DMEM, Mediatech Inc., Manassas, VA, USA), supplemented with heat-activated fetal bovine 
serum (10% v/v) (FBS, Hyclone Lab. Inc., Pittsburgh, PA, USA), penicillin (100 IU/ml) and 
streptomycin (100 μg/ml) in a humidified incubator with 5% CO2 in air at 37 °C.   
3.2.3. PCL Microsphere Fabrication and Cell Adhesion 
Uniform PCL microspheres of 50 µm diameter were fabricated using the precision particle 
fabrication (PPF) method previously described [46, 49, 107]. Briefly, a 5% (w/v) PCL solution in 
DCM and a 1% (w/v) PVA in deionized water, fed into the coaxial nozzle, was acoustically excited 
using an ultrasonic transducer to break up the liquid stream into uniform droplets, which were 
collected in a beaker containing a 1% (w/v) PVA solution in deionized water and hardened 
overnight. Thus-obtained microspheres were washed three times with deionized water and freeze-
dried (Labconco benchtop model, Kansas, MO, USA).   
An agarose-coated 24-well plate was prepared using a sterile warm agarose solution (1% 
w/v) in deionized water and treated with the PCL microspheres at a concentration of 70,000 
spheres per well for a monolayer coverage. NIH 3T3 fibroblasts were plated at a density of 20×104 
cells per well into the plate, and incubated in a culture medium under a humidified incubator with 
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5% CO2 in air at 37 °C. At time points of 1, 3, 6, and 10 h, the cell-sphere aggregates were collected 
from the plate and lightly pelleted in 1.5 mL conical tubes at low 500 rpm, and washed with 
phosphate buffer saline (PBS, Mediatech Inc., Manassas, VA, USA) to remove non-adherent cells. 
The percentage of cell adhesion was quantified by protein assay (BCA protein assay kit, Rockford, 
IL, USA) [108]. 
3.2.4. Microsphere Concentration Optimized for Encapsulation 
AL microcapsules of 500 μm diameter, encapsulating the PCL microspheres, were 
prepared by employing a 2.0% AL solution for the shell and a 1.5% AL solution for the core. To 
the latter, microspheres with concentrations of 10K, 15K, 25K, and 50K spheres/ml were added. 
The encapsulation process is described in the following section. The encapsulation efficiencies are 
expressed as the percent ratio of the number of microsphere-encapsulating AL capsules to a total 
of 500 capsules counted using optical microscopy. 
3.2.5. Cell Encapsulation 
Cell encapsulation was performed by the PPF method previously described [86]. Briefly, 
2.0% (w/v) sodium alginate and 0.3M mannitol was dissolved in deionized water (pH 7.2 – 7.4) 
to prepare a solution for the capsule shell [84]. NIH 3T3 fibroblasts, a passage number of 11, were 
trypsinized and then centrifuged at 3,000 rpm for 5 min. After decanting the medium, the cells 
were re-suspended in a 1.5% alginate solution (50 x 104 cells/ml) containing 0.3M mannitol for 
the capsule core. These AL solutions were fed into the coaxial nozzle to produce a jet, which was 
broken up into uniform droplets by acoustic excitation, and collected in a gelling solution of 50 
mM CaCl2, 1 mM BaCl2, and 0.05% (w/v) Tween 20 in deionized water, pH 7.2 – 7.4. AL 
microcapsules co-encapsulating cells and microspheres (ALMS microcapsules) were prepared by 
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replacing the core solution with a 1.5% AL solution containing both NIH 3T3 fibroblasts and 
microspheres. AL-PLL-AL (APA) microcapsules were prepared by suspending AL capsules in a 
solution of 0.055 (w/v) PLL and 0.45% (w/v) NaCl for 5 min, followed by coating with a 0.1% 
AL solution for 5 min [109]. The liquefaction of the APA capsule core was performed by 
suspending the resulting capsules in 0.055M sodium citrate for 5 min. The resulting capsules were 
washed with PBS and transferred to 24-well plates at a density of 300 capsules per well. 
3.2.6. Characterization of Microspheres and Microcapsules 
Optical (Olympus BX51, Olympus America Inc., Waltham, MA, USA) and scanning 
electron microscopy (Hitachi S4800 High Resolution SEM, Japan) were used to assess the 
morphologies of the PCL microspheres, encapsulated cells and microcapsules described in this 
study. The size and the size distribution of the PCL microspheres and AL microcapsules were 
determined from 500 spheres or capsules for each measurement. For the SEM images of the cells 
adhered to the PCL microspheres, each specimen was fixed with a modified Karnovsky's fixative 
(2% paraformaldehyde and 2% glutaraldehyde in 0.05M PBS) overnight [110].  
3.2.7. Cell Viability and Growth 
Viability of encapsulated cells was assessed by fluorescent staining with SYTO-
green/ethidium bromide (EB) [85, 111]. The stock solutions of SYTO-green (5 mM in DMSO, 
Invitrogen Inc., Waltham, MA, USA) and EB (10 mg/ml in dH2O, Invitrogen Inc., Waltham, MA, 
USA) were stored at -20 °C and room temperature, separately. The working solutions were freshly 
prepared before assay. The encapsulated cells were monitored under a fluorescence microscope 
(Olympus BX51, Olympus America Inc., Waltham, MA, USA). Viability and growth of the 
encapsulated cells were determined by 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium 
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bromide (MTT, Sigma, St. Louis, MO, USA) assay [112].  At time points of Day 0, 1, 2, 3, 7, 10, 
14, 21, and 28, the samples were collected and read on a microplate reader (BioTek Synergy HT 
Fluorescent Microplate Reader, Winooski, VT, USA) at 570 nm with reference 630 nm. The 
culture medium was refreshed every other day during the 28-day period. 
3.2.8. Statistical Analysis 
All data are expressed as mean ± standard deviation (SD) for five replicates. Data 
comparisons were performed by the paired two-tailed Student’s t test. Differences with p < 0.05, 
0.005, or 0.001 were considered statistically significant. 
 
3.3. Results and Discussion 
3.3.1. PCL Microsphere Fabrication and Cell Adhesion to the Microsphere 
Surface 
Fabrication of microspheres that have a suitable size is prerequisite for their co-
encapsulation with cells. Considering the size of NIH 3T3 fibroblasts (10 – 20 μm diameter), PCL 
microspheres of 50 μm diameter were fabricated employing the PPF method [46, 49, 107]. Figure 
3.1 shows the optical and SEM images of the PCL microspheres, demonstrating the 
monodispersity (Cv = 1.57%) and smooth surface morphology of the microspheres fabricated by 
the PPF method. 
Prior to encapsulating the microspheres in the capsules, we examined the adhesion of the 
fibroblasts to the microsphere monolayer, covering the surface of agarose-coated plates. The 
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optical and SEM images in Figure 3.2(a) and (b) show that the cells moved and adhered to the 
sphere surfaces, leading to the formation of cell-particle aggregates. This indicates that the 
migration and adhesion of the cells to the microsphere surface is not a passive occurrence involving 
their simple sedimentation or random contact with the spheres. Figure 3.2(c) shows the progress 
of cell adhesion to the microspheres as a function of time. Most of the cells initially seeded were 
attached to the sphere surface within 10 h, indicating their high affinity to the PCL spheres. Surface 
hydrophobicity is considered to be a crucial factor for governing protein adsorption and subsequent 
cell adhesion and proliferation on the biomaterial surfaces [113, 114]. This supports the 
encapsulation of PCL microspheres as an expanded surface inside the capsules. 
3.3.2. Encapsulation of PCL Microspheres in AL Microcapsules 
Encapsulation efficiency was assessed as a function of sphere concentration to determine 
a suitable microsphere concentration to be encapsulated in AL microcapsules of 500 μm diameter. 
Figure 3.3 shows the optical micrographs of the AL microcapsules encapsulating the microspheres 
of concentrations of 10,000 – 50,000 spheres/ml. Table 3.1 summarizes the encapsulation 
efficiency as a function of microsphere concentration, indicating that no empty capsules were 
produced with 50,000 spheres/ml. 
3.3.3. Morphology, Viability, and Growth of Encapsulated Cells  
The morphology, viability and growth of the fibroblast cells in three different types of 
microcapsules were monitored as a function of time to assess the effect of intracapsular 
environment, i.e., semi-liquid core with microspheres (ALMS), semi-liquid without microspheres 
(AL), and liquid (APA). Figure 3.4(a) shows the optical images of the cell-encapsulating AL, 
ALMS and APA microcapsules. The cells encapsulated in these capsules exhibited growth during 
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the initial 3-day period with no significant difference between the capsule types; however, their 
growth pattern became distinctive afterwards. The cells sporadically formed multiple aggregates 
in the AL as well as the APA capsules.  Between Day 7 to 28, the cells in the AL capsules appeared 
to grow and form smaller clusters as compared to the large clumps that emerged in the APA 
capsules. This may indicate that the cell growth in the liquid core of the latter was improved by 
the less rigid AL matrix as compared to the semi-liquid core of the former [115]. On the other 
hand, the cells in the ALMS capsules exhibited higher cell density than those in the AL and APA 
capsules, suggesting the positive impact of the PCL microspheres on the cell growth promoted by 
cell-substrate interactions. 
Figure 3.4(a) shows the fluorescence images of the encapsulated cells stained with nucleic 
acid SYTO-green/EB, displaying the viability and growth patterns of the cells in the AL, ALMA, 
and APA capsules as a function of time. All types of capsules showed no significant changes in 
the cell viability immediately after encapsulation (Day 0), indicating that the cells experienced 
minimal stress during the encapsulation process. The ALMS capsule displayed a larger proportion 
of fluorescence with higher intensity at 7 days post-encapsulation compared to the AL and APA 
capsules. Figure 3.4(b) shows magnified images of the ALMS capsule shown in Figure 3.4(a), 
revealing that the cells migrate and adhere to the microsphere in the capsule and that the major 
portion of viable cells increases on its periphery. Figure 3.5 shows a schematic of the AL, ALMA 
and APA microcapsules encapsulating cells, illustrating how cells may behave in the semi-liquid, 
microsphere-encapsulating semi-liquid, and liquid core, respectively. Figure 3.6 shows the 
viability of the fibroblast cells in the AL, ALMS and APA microcapsules assessed by MTT assay 
for 4 weeks. Regardless of the capsule type, the cell viability increased until Day 3. Between Day 
3 and 28, the viability of the cells in the AL capsules decreased continuously, especially fast until 
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Day 10, while the decrease in the APA capsules began at Day 7. As a result, significant differences 
between the APA and AL capsules were shown between Day 3 and 10. Although the APA capsules 
exhibited high cell viability until Day 7, as the cell-aggregates increase in dimensions, they are 
susceptible to central necrosis, resulting in the cell viability [116]. On the other hand, the high 
viability of the cells in the ALMS capsules at Day 3 was maintained until Day 28. This is also 
supported by the EB-stained spots in the cell aggregates, shown in Figure 3.4. The improved 
viability of the cells in the ALMS capsules compared to those in the AL and APA capsules implies 
the positive effects of the encapsulated microspheres on the cell viability and growth, altering the 
intracapsular microenvironment to promote cell-cell and cell-substrate interactions. 
 
3.4. Conclusion 
In this study, we encapsulated the NIH 3T3 fibroblast cells, used as a model ADC, in core-
shell AL microcapsules with different core environments, i.e., a semi-liquid core, with or without 
PCL microspheres and liquid-core without microspheres. The cells exhibited increased viability 
and growth in the capsules with a liquid core compared to those with a semi-liquid core in the 
absence of microspheres. However, in the presence of the microspheres in the semi-liquid core, 
the viability and growth of the cells became higher than those in the liquid core, providing an 
expanded surface for the cells to adhere and proliferate. This suggested that the co-encapsulation 
of cell-friendly microspheres could be a promising strategy for the long-term survival and function 
of encapsulated therapeutic ADCs. In addition, the microspheres can be surface-functionalized 
and/or loaded with therapeutic agents, such as drugs, growth factors or genes, for sustained 
intracapsular release.     
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3.5. Table and Figures 
Table 3.1 Encapsulation efficiency of PCL microspheres in alginate microcapsules 
Microsphere Concentration 
[# of microspheres/ml] Encapsulation Efficiencyb) 
10,000 61% 
15,000 75% 
25,000 92% 
50,000 100% 
a) measured from 500 microcapsules. b) (# of microcapsules containing microspheres / total # of microcapsules) × 100   
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Figure 3.1 Optical (a) and SEM (b) micrographs of PPF-fabricated PCL microspheres of 50 μm in diameter. 
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Figure 3.2 (a) Optical micrographs of NIH 3T3 fibroblasts adhered to 50 μmD-sized PCL microspheres as a function of time at 37 °C. Scale bar = 200 μm. (b) SEM micrographs of cells and PCL microspheres, showing a cluster formation. (c) Cells adhered to the PCL microspheres on an agarose-coated plate. The mean of total proteins from initial cell seeding densities was set as 100% (maximum). Data are represented as mean ± SD (n=5). Statistically significant difference as compared to the maximum, *p <0.05 and **p <0.005. 
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Figure 3.3 Optical micrographs of AL microcapsules encapsulating 50 μmD-sized PCL microspheres with concentrations of 10,000 – 50,000 microspheres/ml. Scale bar = 500 μm. 
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Figure 3.4 (a) Optical and fluorescence micrographs of the encapsulated NIH 3T3 fibroblasts in the AL (top pair) and ALMS (middle pair) and APA microcapsules (bottom pair) against time. SYTO-green and ethidium bromide (EB) staining was used after encapsulation to assess viable cells (green) and dead or damaged cells (red). Scale bar = 200 μm. (b) Optical and fluorescence micrographs of the ALMS capsule in (a) at a higher magnification, revealing cell migration and adhesion to the microspheres, and cell-cell and cell-substrate interactions that increase in the periphery of the microsphere as a function of time. Scale bar = 100 μm.   
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Figure 3.5 Schematic of the microcapsules with a semi-liquid core (AL), encapsulating therapeutic cells, a semi-liquid core (ALMS), co-encapsulating cells and microspheres that serve as anchors to induce appropriate cell-cell and cell-substrate interactions, and a liquid core (APA), encapsulating therapeutic cells. 
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Figure 3.6 MTT absorbance of NIH 3T3 fibroblasts in the AL, ALMS and APA microcapsules cultured for 28 days, measured at 570 nm. Data are represented as mean ± SD (n=5). * denotes a statistically significant difference between the viability of cells in the AL or APA capsules and that in the ALMS capsules, *p <0.05, **p <0.005 and ***p <0.001. # denotes a statistically significant difference between the data from the AL capsules and those from the APA capsules, #p <0.05 and ##p <0.005. 
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CHAPTER 4 
SUSTAINED EXENATIDE DELIVERY VIA 
INTRACAPSULAR MICROSPHERES FOR IMPROVED 
SURVIVAL AND FUNCTION OF 
MICROENCAPSULATED PORCINE ISLETS 
 
4.1. Introduction 
The most common form of therapy for type 1 diabetes mellitus (T1DM) involves lifelong 
administration of exogenous insulin and frequent/continuous monitoring of blood glucose levels, 
providing a suboptimal glycemic control at best. Tighter glucose control can be attained through 
whole pancreas transplantation that involves complicated surgical procedures, high morbidity, 
lifelong immunosuppressive medication and consequential complications [117]. Allogeneic islet 
transplantation has emerged as a promising alternative to these treatments. This minimally invasive 
procedure results in no or fewer complications and thus may be utilized for a wider range of 
recipients; however, the success of allogeneic islet transplantation remains questionable due to 
limited supply of human pancreas donors and the graft failure within a relatively short period of 
time compared with whole pancreas transplantation [87, 118]. In this context, transplantation of 
encapsulated porcine islets is an attractive strategy due to donor abundance and accessibility, 
allowing long-term immunoisolation. The semipermeable membrane of microcapsules protects 
inner islets from the recipient’s immune system and allows free exchange of insulin, nutrients, 
hormone, oxygen and waste [76]. Porcine pancreas is considered as a prospective source of islet 
xenografts due to similarities in pig physiology to humans, structural similarity between human 
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and porcine insulin, resistance to recurrent autoimmunity and feasibility for genetic 
immunomodulation [119-121]. Many studies have shown encouraging results in reducing 
xenogeneic rejection and prolonging graft survival time. Nevertheless, there are still several 
challenges before large-scale clinical applications of encapsulated porcine islets such as high-
throughput encapsulation, prevention of hypoxia, and improvement of islet survival and function 
[122-125].  
Glucagon-like peptide-1 (GLP-1) analogs such as exendin-4 have shown to enhance 
glucose-dependent insulin secretion, inhibit cytokine- and hypoxia-induced apoptosis, prevent 
inflammation, stimulate pancreatic beta cell proliferation and neogenesis, decrease glucagon 
production, and delay gastric emptying [126-130]. More importantly, they stimulate the secretion 
of insulin only in the case of high glucose level and consequently prevent the risk of hypoglycemia 
[131]. It was reported that the islet mass required to achieve normoglycemia could be reduced 
significantly by transplanting exendin-4 gene transduced islets by the action of exendin-4 secreted 
at the transplantation site to inhibit apoptosis and enhance insulin secretion [132]. Exendin-4 is 
originally isolated from the salivary secretions of the lizard Heloderma Suspectum and is 
commercially available as approved by the U.S. Food and Drug Administration (FDA) for the 
treatment of type 2 diabetes mellitus (T2DM) [133]. 
In this study, we investigated the effect of locally released exenatide, a synthetic version 
of exendin-4, on the survival and function of porcine islets in alginate microcapsules in vitro for 
21 days, employing co-encapsulated exenatide-loaded microspheres (MSs) as drug depots for on-
site drug release (Figure 4.1). Prior to encapsulation, we fabricated monodisperse exenatide-loaded 
poly(latic-co-glycolic acid) (PLGA) MSs and assessed their release profiles as a function of drug 
loading.    
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4.2. Materials and Methods 
4.2.1. Materials 
Poly(latic-co-glycolic acid) (PLGA) (50:50 lactic acid/glycolic acid; [i.v.]=0.58 dL/g in 
hexafluoroisopropanol) were obtained from Absorbable Polymers (Birmingham, AL, USA).   
Poly(vinyl alcohol) (PVA) (80% hydrolyzed; MW ~6,000) were purchased from Polysciences, Inc. 
Exenatide acetate were obtained from Bachem Americas, Inc. (Torrance, CA, USA). Protanal® 
SF 120 alginate (from Laminaria hyperborea; Mw 237K, FG 0.694) was obtained from FMC 
BioPolymer (Drammen, Norway). Alginate solutions were filtered through cellulose acetate 
membranes with pore sizes of 0.8, 0.45, and 0.22 μm, consecutively. Tween 20 and BaCl2 were 
purchased from Sigma-Aldrich (St. Louis, MO, USA) and CaCl2 was purchased from Fluka (USA). 
All chemicals were used without further purification.   
4.2.2. Fabrication and Characterization of Exenatide-Loaded PLGA MSs 
Exenatide-loaded PLGA MSs were fabricated by the PPF method previously described, 
combining a modified double-emulsion method (W1/O/W2) [46, 49, 107, 134]. Briefly, for 5 and 
10% (w/w) exenatide in PLGA MSs, each corresponding amount of exenatide was dissolved in 1% 
(w/v) PVA solution, which was added to 5% (w/v) PLGA in dichloromethane (DCM) and 
emulsified by sonication for 30 s. The emulsion and 1% (w/v) PVA solution, were fed into the 
coaxial nozzle and broken up into uniform droplets by acoustic excitation. The resulting droplets 
were collected in a collection bath containing a 1% (w/v) PVA solution and hardened for 2 h. 
Thus-obtained MSs were washed three times with deionized water to remove PVA, freeze-dried 
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(Labconco benchtop model, Kansas, MO, USA), and stored in a sealed tube at –20 °C. The 
morphology of the PLGA MSs with 0, 5, and 10% (w/w) loadings was observed by optical 
microscopy (Olympus BX51, Olympus America Inc., USA) and scanning electron microscope 
(Hitachi S4800 High Resolution SEM, Japan). The drug loading and loading efficiency was 
determined by a solvent dissolution method with DCM and acetone [135]. The exenatide amount 
was measured by BCA assay (Thermo Scientific, Waltham, MA, USA).  
In vitro release profile of the MSs was measured by suspending 20 mg MSs in 1 ml of 
assay medium (PBS with 2 mM sodium dodecyl sulfate (SDS)) at 37 °C under continuous agitation 
at 100 rpm. At designed time intervals, the suspension was centrifuged at 6000 rpm for 5 min, the 
supernatant was transferred to a 1.5 ml tube, and an equal volume of fresh medium was added to 
the precipitate for the next assay. The transferred medium was centrifuged at 12,000 rpm for 10 
min. The amount of exenatide in the supernatant was determined by the BCA assay (Thermo 
Scientific, Waltham, MA, USA). Exenatide release from the PLGA microspheres was investigated 
as previously described [136]. 
4.2.3. Porcine Islet Isolation 
Islet isolation was performed by modifying the Ricordi method [82], using the pancreas of 
4 – 6 month old pigs from the Meat Science Laboratory at the University of Illinois. Briefly, the 
pancreas was perfused and digested with Hanks' balanced salt solution (HBSS) with 10% fetal 
bovine serum (FBS) containing collagenase (from Clostridium histolyticum, Sigma, St. Louis, MO, 
USA), followed by filtration, centrifugation and discontinuous Ficoll® 400 (Sigma, St. Louis, MO, 
USA) density gradient centrifugation. The isolated islets were resuspended in RPMI-1640 
containing 10% FBS and 1% Pen/Strep for incubation at 37°C in 5% CO2. Isolation outcome was 
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evaluated by converting islets to islet equivalents (IEQ) with an average diameter of 150 µm (3,918 
IEQ/g). Islet viability after isolation and overnight recovery was 96.4 ± 0.7% and 93.4 ± 3.4%, 
respectively [137, 138].  
4.2.4. Islet Encapsulation 
Alginate capsules were prepared by modifying the PPF method previously described [86]. 
Briefly, a 2.0% (w/v) Protanal® SF 120 sodium alginate solution was prepared in dH2O (pH 7.2 – 
7.4) as a shell solution. Isolated porcine islets were centrifuged at 3,000 rpm for 5 min at room 
temperature. After decanting the medium, the islets were re-suspended in a 1.5% alginate solution 
(10,000 islets/ml), used as a core solution. The alginate solutions were fed into the coaxial nozzle 
to produce a jet, which was broken up into uniform core/shell droplets and collected in a gelling 
solution containing 50mM CaCl2, 1mM BaCl2 and 0.05% (w/v) Tween 20 in dH2O (pH 7.2 – 7.4). 
Alginate microcapsules co-encapsulating islets and exenatide-loaded PLGA MSs were prepared 
by replacing the core solution with a 1.5% alginate solution containing both islets (10,000 islets/ml) 
and MSs (1.5 mg/ml). The resulting capsules were washed with PBS and transferred to RPMI-
1640 containing 10% FBS and 1% Pen/Strep for incubation at 37 °C in 5% CO2. Optical images 
were used to determine the size and size distribution of the capsules, analyzing >200 capsules. 
4.2.5. In Vitro Evaluation of Encapsulated Islets 
At scheduled time points, viability and function of encapsulated islets were assessed by 
trypan blue exclusion and insulin secretory response during glucose stimulation, respectively [137-
139]. For in vitro GSIS assessment, encapsulated islets of 500 IEQ were separately exposed to 
1.67 mM low glucose or 16.7 mM high glucose for 60 min at 37°C in 5% CO2. Insulin levels were 
determined with porcine insulin ELISA assay kit (Mercodia, Uppsala, Sweden) and expressed as 
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stimulation index (SI), calculated as the ratio of high to low GSIS. The morphology of 
encapsulated islets was observed using an optical microscope (Olympus BX51, Olympus America 
Inc., USA) at the scheduled time points. 
4.2.6. Statistical Analysis 
All data are expressed as mean ± standard deviation (SD) for four replicates. Data 
comparisons were performed by one-way ANOVA with Tukey’s post hoc test for multiple 
comparisons. Differences with p < 0.05 were considered statistically significant. 
 
4.3. Results and Discussion  
4.3.1. Characterization of Exenatide-Loaded PLGA MSs and In Vitro Release  
PLGA has been widely used as a medical-grade biodegradable polymer in surgical sutures, 
bone plates, orthopedic implants and drug delivery system [140-142]. We fabricated exenatide-
loaded MSs employing PLGA as a carrier material. Table 4.1 summarizes the drug loading, 
loading efficiency and size of exenatide-loaded PLGA MSs, prepared by the PPF method. The 
loading efficiency was ~ 85% for a 5% theoretical loading although it decreased to ~80% as the 
loading increased to 10%. The size of the MSs increased with the exenatide loading, which is 
supported by the optical images of blank and exenatide-loaded PLGA MSs shown in Figure 4.2 
All MSs were monodisperse with Cv < 2.2 %. Particle uniformity is one of the critical requirements 
for polymeric drug delivery systems, enabling controlled drug release kinetics [46].  
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The effect of exenatide loading on drug release from the MSs was investigated. Figure 4.3 
shows drug release profiles of the PLGA MSs with 5 and 10% (w/w) theoretical loadings of 
exenatide. The exenatide-loaded MSs exhibited a low initial release, i.e., 11 – 13%, within 24h 
compared to the burst release (11 – 65%) reported by others [134, 141, 143, 144]. In addition to 
the properties pertaining to polymer, other parameters such as drug loading, internal aqueous 
volume, surfactant concentration and preparation method, would affect the drug release behavior 
of microsphere-based delivery system [134, 145]. The minimal burst release exhibited by the 
PLGA MSs could be attributed to the controlled sphere size, stable positioning and small volume 
of the internal water phase in the MSs, dense MS surface during the solidification process. 
Cumulative 100% release from the 5 and 10% (w/w) exenatide-loaded MSs was achieved in 18 
and 23 days, respectively.  
4.3.2. Morphology, Viability, and Function of Encapsulated Islets  
Previously, we reported the fabrication of bacterial cell-encapsulating alginate 
microcapsules by the PPF method, confining the cells in the capsule core [86]. The PPF method 
was employed to encapsulate porcine islets in alginate (AL) microcapsules with no islet protrusion. 
To investigate the effect of sustained delivery of exenatide on the encapsulated islets for 21 days, 
AL microcapsules co-encapsulating 10% (w/w) exenatide-loaded MSs (extMS) with porcine islets 
were fabricated. Figure 4.4 shows the optical images of the islets encapsulated in the AL and the 
AL-extMS capsules. The capsules were spherical with a mean diameter of 411.0 ± 11.6 μm with 
no islet protrusion. No notable physical difference was observed between the islets encapsulated 
in the AL and those in the AL-extMS capsules until Day 7; however, the islet morphology became 
distinctive for each capsule type afterwards. In the AL capsules from Day 10 to 21, individual cells 
protruded from the islet surface to detach from the islet, indicating decreased or decreasing health 
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[146]. The islets in the AL-extMS capsules maintained their morphological integrity until Day 21. 
Figure 4.5(a) shows the viability of the islets encapsulated in the AL and the AL-extMS capsules 
for 21 days. The viability of islets after isolation and overnight recovery was 93.4 ± 3.4%, and that 
after the encapsulation in the AL and AL-extMS capsules (Day 0) 90.8 ± 3.5% and 91.6 ± 3.6%, 
respectively, revealing minimal stress during encapsulation. There was no significant difference 
in the viability between the islets in the AL and the AL-extMS capsules at Day 1 post-
encapsulation. The viability of the islets in the AL capsules began to decrease at Day 3 and that in 
the AL-extMS capsules at Day 5. The islets in both capsules maintained > 80% viability at Day 5, 
however, the islets in the former began to decrease rapidly afterwards to show 76.8 ± 3.8% viability 
at Day 7. Thereafter the viability gap between the islets in the AL and the AL-extMS capsules 
became wider. As a result, at Day 10, the islets in the AL and the AL-extMS capsules exhibited 
69.7 ± 3.6% and 82.3 ± 3.3% viability, respectively, and at Day 21, 45.1 ± 4.9 % and 71.1 ± 4.8 %, 
respectively, manifesting the beneficial effect of the latter on islet viability. To assess the effect of 
the AL-extMS capsules on islet function, we measured the glucose-stimulated response of the 
islets to low or high glucose concentrations to determine the stimulation indices (SIs) presented in 
Figure 4.5(b). At Day 1, no significant difference in the SIs was observed between the islets in the 
AL and the AL-extMS capsules. The SI of the former began to decrease at Day 3 and showed a 
severe decrease at Day 7, suggesting islet β-cell failure [147]. In contrast, the latter maintained 
high SIs during the 21-day period, consistent with the viability data shown in Figure 4.5(b). This 
demonstrated the positive effect of intracapsular sustained delivery of exenatide on improving the 
survival and function of the encapsulated porcine islets. 
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4.4. Conclusion 
We herein described the effect of sustained on-site release of exenatide on enhancing islet 
survival and function, enabled by exenatide-loaded PLGA MSs co-encapsulated with porcine islets. 
The exenatide-loaded PLGA MSs exhibited a narrow size distribution and sustained release profile 
during the 21-day period with low initial burst. The porcine islets co-encapsulated with the 
exenatide-loaded MSs in alginate microcapsules showed longer survival and improved function. 
This implies that the microsphere-mediated on-site release of exenatide could reduce graft-related 
complications, mitigating the adverse effects of systemic exenatide. 
 
  
 52 
4.5. Table and Figures 
Table 4.1 Drug loading and loading efficiency of exenatide-loaded PLGA MSs 
Theoretical loading 
[%, w/w] 
Drug loadinga) 
[%, w/w] 
Loading efficiencyb) 
[%] 
Microsphere size 
Mean diameter ± SD [µm] 
0 0 0 40.92 ± 0.83 
5 4.20 ± 0.25 84.06 ± 5.09 45.41 ± 0.97 
10 7.91 ± 0.55 79.08 ± 5.50 51.67 ± 1.10 
 
a) Loading amount (%, w/w) = ୛ୣ୧୥୦୲ ୭୤ ୣ୶ୣ୬ୟ୲୧ୢୣ ୧୬ ୫୧ୡ୰୭ୱ୮୦ୣ୰ୣୱ୛ୣ୧୥୦୲ ୭୤ ୣ୶ୣ୬ୟ୲୧ୢୣି୪୭ୟୢୣ  ୫୧ୡ୰୭ୱ୮୦ୣ୰ୣୱ  ×  100 
b) Loading efficiency (%) = ୅ୡ୲୳ୟ୪ ୪୭ୟୢ୧୬୥ ୟ୫୭୳୬୲୘୦ୣ୭୰ୣ୲୧ୡୟ୪ ୪୭ୟୢ୧୬୥ ୟ୫୭୳୬୲  ×  100 
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  Figure 4.1 A schematic of alginate microcapsules co-encapsulating porcine islets and exenatide-loaded microspheres that serve as microdepots to locally deliver exenatide at the site of islet xenotransplantation.   
 54 
  Figure 4.2 Optical (top layer) and SEM images (bottom layer) of (a,e) blank, (b,f) 5, and (c) 10% (w/w) exenatide-loaded PLGA MSs, fabricated by the PPF method combined with W1/O/W2 double emulsion. Scale bar = 50 μm.   
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  Figure 4.3 In vitro cumulative drug release profiles of the exenatide-loaded PLGA MSs with 5 and 10% (w/w) exenatide. Data are represented as mean ± SD (n=4). 
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Figure 4.4 Optical images of the porcine islets encapsulated in AL (1 and 3 layers) and AL-extMS (2 and 4 layers) microcapsules against time. Black arrows indicate exenatide-loaded PLGA MSs. Scale bar = 100 μm. 
  
 57 
0 5 10 15 200
40
50
60
70
80
90
100
  
 
 
 AL AL-extMS
Time (day)
Via
bilit
y (%
)
* *** *** ***
***
(a)
 
0.0
0.5
1.0
1.5
2.0
2.5
3.0(b)
**
***
21
******
14107531
 
 
 AL AL-extMS
Stim
ulat
ion
 Ind
ex (
SI)
Time (day)0
*
   
Figure 4.5 (a) Viability of porcine islets in AL and AL-extMS microcapsules for 21 days of culture, measured by trypan blue exclusion. (b) Stimulation index of the islets encapsulated in the AL and AL-extMS capsules for 21 days. Data are represented as mean ± SD. * denotes a statistically significant difference between the AL and AL-extMS data, *p <0.05, **p <0.005 and ***p <0.001. 
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CHAPTER 5 
CONTROLLED RELEASE OF PANTOEA 
AGGLOMERANS E325 FOR BIOCONTROL OF FIRE 
BLIGHT DISEASE OF APPLE1 
 
5.1. Introduction 
Fire blight is a serious disease of apple and pear, and has been a major deterrent to their 
commercial production in various regions around the world. It is the single most devastating 
bacterial disease of these crops, and it is caused by presence of high levels of epiphytic populations 
of Erwinia amylovora (Ea) on floral surfaces [148, 149]. Bacteria initially colonize stigmatic 
surfaces of flowers of apples and pears. Although colonization is limited by the availability of 
moisture, rain or heavy dew allows this bacterium to migrate downward along the floral style and 
invade nectarthodes of the hypanthium [150]. Presence of large intercellular spaces among 
stigmatic papillae provides a nutrient-rich environment for multiplication or proliferation of 
bacterial cells, including those beneficial organisms that are antagonistic to Ea. As an initial 
strategy to suppress the blossom-blight phase of fire blight, streptomycin has been used as an 
effective antibiotic; however, resistance of Ea to this antibiotic has become very common in many 
production areas [151, 152]. More importantly, this has also raised concerns about the potential 
impacts of agricultural use of antibiotics on human health [153]. For these reasons, the use of 
                                                          This chapter has been adapted from I. Y. Kim, P. L. Pusey, Y. Zhao, S. S. Korban, H. Choi, and K. Kim, “Controlled release of Pantoea agglomerans E325 for biocontrol of fire blight disease of apple,” J Control Release, vol. 161, pp. 109-15, Jul 10 2012. 
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biocontrol agents, such as bacterial antagonists, has been investigated as an alternative to 
antibiotics [154-156]. Strains of Pantoea agglomerans have attracted special attention as potential 
biocontrol agents for fire blight, as they are excellent colonizers of stigmas of apple and pear, and 
they effectively inhibit multiplication of Ea [157-159]. 
Pusey et al. [156, 160-163] have reported that, compared to other organisms tested, P. 
agglomerans strain E325 (E325) provides an exceptionally high suppressive activity against 
populations of Ea on stigmas of detached crab apple flowers. The two primary mechanisms for 
this activity are competition for space and nutrients and production of a peptidic metabolite that 
inhibits pathogen growth [160, 164]. In spite of significant suppression of the pathogen Ea by the 
bacterial antagonist E325, its effect on blossom blight in field trials has been inconsistent due to 
instability of established antagonist populations, environmental conditions, natural dispersal of 
antagonists, and/or various physiological changes associated with flower development and 
senescence [163]. Therefore, protection of living antagonists within a physical barrier against 
adverse environmental conditions is a viable approach that is worthy of consideration. The idea of 
encapsulating living cells was originally proposed by Chang [165] for immunoprotection of 
transplanted animal cells, which subsequently led to the development of a number of encapsulation 
technologies for applications in the pharmaceutical, chemical, and food industries, as well as in 
agriculture, biotechnology, and medicine [2-6]. Cells, encapsulated together with nutritional 
additives [166], could be protected from toxic compounds and adverse conditions in the 
environment [167] and improve their physiological activity, thus leading to higher cell viability 
[168]. To adapt microencapsulation for biocontrol of fire blight, encapsulated bacterial cells must 
be: (a) confined safely within capsules, maintaining their viability and activity until the time of 
release; (b) protected from adverse environmental conditions, such as low moisture and UV 
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radiation during application and initial establishment, particularly during the daytime; and (c) 
protected from chemicals such as blossom thinning agents. Size and porosity of capsules will 
influence release profiles of biocontrol agents. The capsule size is also important in capsule-based 
delivery to efficiently cover the target area of blossoms. The duration for apple flowers to be highly 
receptive to microbial colonization is relatively short, typically 3 to 4 days following petal 
expansion. Therefore, it is crucial for the E325 cells to be released within this time period. It is 
pointed out that E325 is exempt from the requirement of a tolerance by EPA and that it does not 
pose an incremental dietary and non-dietary risk to the adult human U.S. population, children, and 
infants. E325 is ubiquitous in the environment and recognized as an epiphyte of a wide variety of 
plants [169].  
In this study, we encapsulated E325 in uniform core-shell alginate microcapsules (AMCs) 
of precisely controlled sizes (60 to 300 μm), and studied their release characteristics and viability. 
Alginate was chosen as the capsule material due to its biocompatibility, non-toxicity, mild 
conditions for gelation, low immunogenicity, and biodegradability. Purified alginate has been 
widely used in the pharmaceutical and food industries, as well as for biomedical and therapeutic 
purposes [3, 170]. In addition, multiplication of E325 cells within AMCs and their post-release 
migration on stigmatic tissues of apple flowers towards the hypanthium were observed using rfp-
labeled P. agglomerans strain E325 (rfp-E325). 
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5.2. Materials and Methods 
5.2.1. Materials 
Sodium alginate, Tween 20, and CaCl2 were purchased from Sigma-Aldrich (Milwaukee, 
WI, USA). SYTO-green (5 mM in DMSO) and ethidium bromide (EB) (10 mg/ml in dH2O) were 
purchased from Molecular Probes Inc. (Eugene, OR, USA) and Invitrogen (Carlsbad, CA, USA), 
respectively. All chemicals were used without further purification, except for sodium alginate 
which was dissolved in dH2O and filtered through cellulose acetate membranes with pore sizes of 
0.8, 0.45, and 0.22 μm, consecutively.  
5.2.2. Bacterial Strain and Culture Conditions 
P. agglomerans strain E325 was originally isolated from ‘Gala’ apple blossoms in orchards 
near Wenatchee, WA, in 1994 [156]. Strain E325 was transformed with a plasmid carrying the rfp-
gene (pMP4662) [171]. E325 labeled with rfp was used to allow in vivo observation of the 
antagonist on viable plant tissues without any staining. Both E325 and rfp-E325 are spontaneous 
antibiotic-resident derivatives generated at the source laboratories. E325 and rfp-E325 are resistant 
to rifampicin and tetracycline, respectively. The bacteria were stored in 15% glycerol at −70 °C, 
and initially incubated in Luria-Bertani (LB) broth, containing 10 g/l tryptone, 5 g/l yeast extract, 
and 5 g/l sodium chloride in dH2O, for 24 h at 28 °C on an orbital shaker at 150 rpm. Cells in 
medium were diluted with an alginate solution for microencapsulation. Bacterial levels in the final 
alginate solution were estimated at 1.6 x 109 colony forming units (CFU) per milliliter by dilution 
plating on LB plates at 28 °C for 24 h.  
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5.2.3. Microencapsulation 
E325 microencapsulation was performed by modifying the PPF method. Briefly, the 
alginate solution was prepared to final solutions of 0.8 – 2.0% w/v with 0.5% w/v of LB broth 
containing cells at pH 7.2 – 7.4. Two alginate solutions were fed separately into inner and outer 
sections of the coaxial nozzle, as core and shell solutions, respectively, to produce a coaxial jet, 
which, in turn, was broken up into uniform droplets by acoustic excitation. The resulting droplets 
were collected and gelled in a bath containing 100 mM CaCl2 for 10 min. AMCs containing E325 
cells were washed three times with PBS consisting of 100 mM CaCl2 before transfer to 6-well 
polystyrene plates for incubation at 4, 15, and 25 °C. 
5.2.4. Characterization 
The morphology of AMCs was observed using an optical microscope (Olympus BX41, 
Olympus America Inc., USA), under bright field, as well as a scanning electron microscope 
(Hitachi S4800 High Resolution SEM, Japan). Optical images were used to determine size as well 
as size distribution of AMCs. Each measurement included at least 500 AMCs. For SEM images, 
AMCs were fixed with a modified Karnovsky's fixative (2% paraformaldehyde and 2% 
glutaraldehyde in 0.05 M PBS) overnight [172], followed by washing three times with 0.05 M 
PBS and fixing with 1% osmium tetroxide for 10 min. The resulting AMCs were washed with 
dH2O, dehydrated with graded concentrations (50, 70, 80, 90, and 100% v/v) of ethanol, and 
treated with hexamethyldisilazane for 20 min. Some capsules were subject to freezing in liquid N2 
and cut using a razor blade prior to dehydration. 
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5.2.5. Cell Viability 
Viability of encapsulated E325 cells was assessed by fluorescent staining with SYTO-
green/EB [85]. Briefly, AMCs containing E325 and LB broth were prepared by feeding alginate 
solutions of 1.0 and 2.0% concentration into the inner and outer nozzles of the microencapsulation 
system, respectively, and cross-linking the resulting liquid core-shell microcapsules in a collection 
bath containing CaCl2. Stock solutions of SYTO-green and EB were stored at −20°C and at room 
temperature, respectively, from which working solutions were freshly prepared prior to assay. 
AMCs containing E325 were washed with PBS and re-suspended in 2 ml of PBS, followed by 
addition of 200 μl SYTO-green and 100 μl EB, consecutively. Encapsulated cells were examined 
under a fluorescence microscope (Olympus IX81, Olympus America Inc., USA). Cells with green 
fluorescence were deemed to be viable and those with red fluorescence dead.  
5.2.6. Release of E325 Bacteria 
To investigate the release of encapsulated E325, AMCs containing E325 were transferred 
to 6-well polystyrene plates with meshes of 70 µm pores [108], and then re-suspended with PBS 
along with gentle shaking at room temperature. A cell release study was performed at 4 °C using 
AMCs produced with alginate solutions of 2.0, 1.5, 1.2, and 1.0% concentration using 20,000 
capsules (2.3 x 107 CFU)/well. The release study was also performed at temperatures of 4, 15, and 
25 °C using 56,000 capsules (2.67 x 107 CFU)/well. The release medium was collected and 
replaced by an equal volume at each sampling time. Cell count in each medium was determined 
by dilution plating on LB plates at 28 °C for 24 h. Initial counts of the encapsulated bacteria were 
determined by re-liquefaction of AMCs in PBS consisting of 150 mM sodium citrate followed by 
gentle shaking at room temperature for 5 min. 
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5.2.7. Multiplication of E325 within AMCs and on Stigmatic Surfaces of Apple 
Flowers 
To observe multiplication of bacterial cells within AMCs and determine their populations 
on stigmatic surfaces of apple flowers following their release, P. agglomerans strain E325 labeled 
with rfp (rfp-E325) and flowers of apple cultivar Gala (Malus × domestica) were used [156]. 
Briefly, AMCs were prepared by feeding 1.0% alginate solution into inner and outer nozzles of 
the microencapsulation system. The inner solution was also blended with LB broth to a final 
concentration of 0.5%. The resulting AMCs, 80 μm in diameter, were loaded onto apple flowers 
by touching each stigma with a droplet of AMCs suspended in PBS, which were subsequently 
incubated at 24 °C and 65% relative humidity. At scheduled time points, fluorescent bacterial cells 
within AMCs and on stigmatic surfaces of apple flowers were examined under a fluorescence 
microscope (Olympus IX81).  
 
5.3. Results and Discussion 
5.3.1. Size-Controlled and Uniform Microencapsulation 
Alginate, employed as a 3-D structure-forming polymer with multivalent ions, is the most 
widely used and characterized biomaterial for cell encapsulation. To generate core-shell drops, 
alginate solutions provided from two separate syringe pumps were combined into a coaxial jet 
configuration using a coaxial nozzle. The resulting coaxial jet, with differing properties, was 
subsequently broken up into a train of uniform core-shell droplets by acoustic excitation at a rate 
of ca. 1,000 – 4,000 drops/sec. Relative flow rates of the two coaxial jet streams were varied to 
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control the core diameter and shell thickness of core-shell microcapsules, thus the overall capsule 
size. Once uniform core-shell droplets were formed, they were hardened by calcium ions (Ca2+).  
Size control of microcapsules is one of the critical requirements to meeting the desired 
controlled release of E325. Figures 5.1(a) and (b) show optical micrographs of AMCs 
encapsulating E325, 120 and 300 μm in diameter, produced from 2.0% alginate solution for the 
shell and 1.0% alginate containing E325 and LB broth for the core. These micrographs clearly 
show that the capsule size is both uniform and controllable. As areas of stigmatic and hypanthial 
surfaces of a single flower are approximately <1 mm2 and 2-3 mm2, respectively, AMCs of 100 
μm diameter can easily and conveniently cover these critical flower parts. It is important to note 
that smaller microcapsules are more likely to maintain cell viability due to lower resistance to 
transport of oxygen, nutrients, and metabolites, and possess greater mechanical strength and higher 
biocompatibility [173, 174]. Figure 5.1(c) and (d) show the SEM micrographs of dried 
microcapsules, 120 μm in wet diameter, revealing the presence of E325 both along the outer 
surface and within the interior cavity of these capsules. Drying of capsules has yielded irregular 
surfaces and has decreased the volume to 62.5% (Figure 5.1(c)), which could be restored upon re-
swelling. The images in Figure 5.1(d) show E325 aggregation within a capsule and its release from 
the capsule during sample preparation. These images indicated that capsules not only retained the 
bacterial cells but also allowed their release.  
5.3.2. Viability of Encapsulated E325 
Viability of the E325 encapsulated in 120 and 300 μm-sized AMCs was investigated using 
the SYTO and EB staining to assess the potential influence of capsule size on dye penetration into 
the capsule [175]. Optical and fluorescence micrographs shown in Figure 5.2 exhibited absence of 
 66 
dead cells, indicating that E325 experienced minimal stress during the encapsulation process and 
that transport of oxygen, nutrients, and metabolites took place via diffusion.  
Presence of a soft core with sufficient nutrients permits cell movement, which in turn 
contributes to the release of bacterial cells from the microcapsule. Indeed, E325 cells have moved 
freely within the capsule. It is likely that during hardening of core-shell droplets in the 
collection/gelation bath, the Ca2+ ions have diffused from the bath into each droplet such that 
hardening is highest along the surface and decreases as Ca2+ ions move toward the droplet center. 
This, combined with corresponding higher and lower alginate concentrations of the shell and core, 
has yielded higher and lower mass densities in the shell and core, respectively. As a result, bacterial 
cells introduced into the core during the droplet generation process largely remain within the soft 
core region during the gelation process. For these reasons, the present microencapsulation scheme, 
based on the core-shell architecture, is highly effective in encapsulating bacterial cells and 
providing a nurturing environment to promote their viability and multiplication.  
5.3.3. Controlled Release of E325 from AMCs 
While microencapsulation of bacterial cells using core-shell microcapsules is an important 
step toward successful biocontrol of fire blight, the most critical milestone remains the controlled 
release of the biocontrol agents. Apple flowers are short-lived, and the bloom period is the only 
time when their stigmas are capable of supporting bacterial growth. On the other hand, the optimal 
time for bacterial colonization is the first few days following petal expansion. To investigate the 
release profiles of the encapsulated E325, 100 μm-sized AMCs encapsulating E325 were prepared 
by employing 1.0 – 2.0% alginate solutions for the shell and 1.0% solution containing E325 and 
LB broth for the core. Figure 5.3(a) shows the release of E325 studied at 4 °C, indicating that the 
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release rate increased as the concentration of the shell solution decreased, which would be 
attributed to the increase in pore size with the decrease in alginate density. Accumulated cell 
release measured as a function of time shown in Figure 5.3(b) illustrates that the E325 release from 
1.0% AMCs was almost completed within 24 to 72 h. This is particularly important in light of the 
relatively short period for apple flowers to be receptive to microbial colonization, thus making it 
most appealing for biocontrol of fire blight. It must be pointed out that E325 populations in AMCs 
have increased during the monitoring of cell release, which is a significant advantage of the present 
microencapsulation approach. The multiplication of E325 facilitated within the confines of AMCs 
could be attributed to the porous matrix of the alginate hydrogel containing LB broth, providing 
the space and nutrients. 
Since the flowering period for apple and the longevity of individual flowers largely depend 
on environmental factors, such as temperature and relative humidity, applying E325 encapsulated 
in AMCs for fire blight control requires more than timely release of disease control agents. For 
example, relative humidity is usually lowest during the day when the temperature is highest; 
whereas, it is highest during the night when the temperature is lowest. Conditions of floral surfaces 
are most favorable for bacterial colonization and multiplication, including those of antagonists, 
when both temperature and moisture levels are high. Bacteria can gain sufficient moisture from 
the stigma for relatively high growth rates during warm days even when the relative humidity is 
low. For these reasons and based on the results in Figure 5.3, AMCs prepared with 1.0% alginate 
solution for the shell were judged to be suitable for effecting bacterial colonization during the first 
few days following petal expansion. To investigate the effect of core solution concentration on 
E325 release, 0.8 and 1.0% alginate solutions were used for the core to produce AMC 1:0.8 and 
AMC 1:1, respectively. Cell release from these AMCs was monitored in PBS at scheduled time 
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intervals at 4, 15, and 25 °C. Figure 5.4 shows that cell release from AMC 1:0.8 was almost 
complete within 6 h whereas it took 12 h for AMC 1:1, indicating higher release rate from the 
former at all temperatures. These release characteristics are a manifestation of combined effects of 
Ca2+ concentration and alginate density affecting shell thickness and pore size of AMCs. The 
release profiles indicated that major portions of E325 were released from AMC 1:0.8 at the initial 
stage giving rise to smaller amounts of release afterwards at all temperatures, as compared to AMC 
1:1. It is to be noted that bacterial multiplication continues within AMCs and in the release medium, 
accelerated with temperature during the monitoring of cell release, leading to cumulative releases 
from both AMCs exceeding 100% of initially encapsulated cells. At 25 °C, the proliferation of the 
unreleased cells remaining in AMC 1:1 at 3 h would contribute significantly to the number of cells 
released, explaining the large amount released observed at 6 h.   
The present results suggested that to allow antagonists to colonize most effectively during 
petal expansion which typically lasts 3 to 4 days, both AMC 1:0.8 and 1:1 would be applicable in 
a field trial for fire blight control. However, the specific choice of AMCs should depend on 
environmental conditions, such as temperature and relative humidity. For example, AMC 1:0.8 
could be selected for a fast release of E325 promoting their initial establishment in windy areas or 
areas with relatively short flower duration, whereas AMC 1:1 could be applied for protection and 
prolonged release of E325 in areas with strong UV radiation and low moisture. Controllable release 
profiles facilitated by separate adjustment of core and shell solutions, therefore, enable substantial 
application flexibility.  
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5.3.4. Multiplication of E325 in AMCs and Colonization of Released E325 on 
Stigmas 
Multiplication of the E325 cells within AMCs and their migration after release onto 
surfaces of stigmatic tissues, towards the hypanthium, were investigated using AMC 1:1 with a 
diameter of 80 μm. The observation was facilitated by using P. agglomerans strain E325 
transformed with a plasmid carrying the rfp-gene (pMP4662) (rfp-E325) [176]. Optical and 
fluorescence images of the AMCs encapsulating the rfp-E325 are shown in Figure 5.5 as a function 
of time, indicating that the AMCs are uniform in size and that the cells, encapsulated together with 
nutritional additives, continuously multiply within AMCs until or during release. Since the capsule 
diameter is 80 μm and the surface area of the stigma of the apple flower is less than 1 mm2, AMCs 
could adequately cover individual stigma. Figure 5.6 shows the optical and fluorescence images 
of stigmas and styles of apple flowers recorded immediately after and at 6 h intervals following 
application of AMCs onto these stigmas. As shown in the fluorescence images, the cells were 
released from AMCs immediately after their application to the stigma (0 h), and continued to 
multiply and colonize the areas of stigmas and styles for 72 h following the establishment on 
stigmatic surfaces, migrating towards the nectar cup. 
To assess the effect of microencapsulation on the viability of E325, free E325 and E325 
encapsulated in AMC 1:1 (E325-AMC) were applied on stigmas of detached blossoms of Gala 
apple. Populations of E325 and E325-AMC both increased exponentially during the initial 24h 
under relative humidity of 65% (Figure 5.7) with the gap between them continuously widening 
with time. Considering that maximum populations of bacterial strains (A506, C9-1, Ea153) in the 
flowers are generally between 106 and 107 CFU [156], the present in vivo results suggest that 
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AMCs have played an important role as a physical barrier for the bacterial cells against adverse 
environmental conditions, provided expanded surface area and nutritional additives for their 
multiplication, and enabled sustained cell release. This demonstrated that microencapsulation of 
antagonists using core-shell AMCs is a viable approach for biocontrol of fire blight. 
5.4. Conclusions 
One-step microencapsulation and controlled release of the bacterial antagonist P. 
agglomerans strain E325 has been investigated using core-shell alginate microcapsules as a 
delivery system for biological control of fire blight. The present encapsulation strategy has 
demonstrated many capabilities. These include fabrication of precisely size-controlled alginate 
capsules 60 to 300 μm in diameter, realizing custom-tailored core-shell structures by single-step 
processing without producing empty capsules and damaging cells. Furthermore, profiles of cell 
release from AMCs are most conveniently controlled by separately adjusting alginate 
concentrations of the outer (shell) and inner (core) solutions in the encapsulation system, rendering 
it potentially most effective for fire blight management. The unique combination of controlled 
release of bacterial cells from AMCs, their multiplication within AMCs, and their colonization 
from stigma to flowers as demonstrated in this work provides support for the hypothesis that 
microencapsulation of antagonists is a potentially promising option for biocontrol of fire blight 
and other plant diseases. The methods described could possibly have additional applications in 
agriculture or food industry.  
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5.5. Figures 
 
 
Figure 5.1 Optical ((a) and (b)) and SEM ((c) and (d)) micrographs of AMCs encapsulating E325, produced from 1.0% alginate solution containing E325 and LB broth fed into the inner region and 2.0% solution into the outer region of the coaxial nozzle.  
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Figure 5.2 Optical (top) and fluorescence (bottom) micrographs of encapsulated E325 under (50x ((a), (c)) and 200x ((b), (d)) magnification. Cell viability was determined by SYTO-green and EB after the encapsulation. It is evident from fluorescence micrographs that all capsules contained viable E325. (b) and (d) are the magnified images of (a) and (b), respectively.  
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Figure 5.3 Release of E325 from the AMCs of 100 μm diameter (a) and their accumulated release (% of the initially encapsulated cells) (b) in PBS at 4 oC. AMCs were produced with alginate concentrations of 2.0, 1.5, 1.2, and 1.0% for the outer (shell) solution and the same inner (core) solution containing E325 at 1.6 x 109 CFU/ml in 1.0% alginate and LB broth.  
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Figure 5.4 Release of E325 from the AMCs produced with alginate concentrations of 0.8% (AMC 1:0.8) (a) and 1.0% (AMC 1:1) (b) for the inner solution containing E325 at 1.67 x 109 CFU/ml in LB broth and the outer solution containing 1.0% alginate concentration. Release of E325 from the AMCs in PBS at the scheduled time intervals at 4, 15, and 25 oC and their corresponding accumulated releases (% of the initially encapsulated cells) (right).    
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Figure 5.5 Optical and fluorescence micrographs of the AMCs encapsulating rfp- E325 under 50x (1st line) and 200x (2nd and 3rd lines) magnification. Each column corresponds to 0 (immediately after encapsulation), 1, 2, and 3 days.  
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Figure 5.6 Stigma colonization by rfp-E325 released from the AMCs. Strain E325 (pMP4662) was visualized under fluorescence microscope immediately after encapsulation (0 h) and at 6, 12, 24, 48, and 72 hours after application. Scale bar = 100 μm.  
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Figure 5.7 Survival of free E325 and E325-AMC on stigmas of detached blossoms of Gala apple. 
Mean populations per flower are presented for E325 (■) and E325-AMC (●) for 72h.  
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CHAPTER 6 
MICROCAPSULE-MEDIATED DELIVERY OF PANTOEA 
AGGLOMERANS E325 TO CONTROL FIRE BLIGHT OF 
APPLE AND PEAR TREES 
 
6.1 Introduction 
Fire blight is a destructive disease caused by the pathogen Erwinia amylovora (Ea), and 
has been a major deterrent to commercial production of apples and pears worldwide [177]. The 
disease was first observed in 1780 [178] and has spread to over 40 countries [179, 180]. An initial 
strategy for the suppression of fire blight was the application of streptomycin as an effective 
antibiotic. However, it did not affect the bacterial community structure, but resulted in the 
abundance of resistance genes in many production areas [151, 152]. More importantly, the 
potential threat of antibiotics to human health is still the subject of debate [153]. In this context, 
bacterial biocontrol of the blossom blight phase of fire blight is a promising alternative to 
antibiotics, which has been demonstrated and subsequently become commercially available [156, 
181, 182]. In particular, strains of Pantoea agglomerans have attracted attention as potential 
antagonists for fire blight [157-159]. 
P. agglomerans strain E325 (E325), originally discovered by P. L. Pusey, showed excellent 
efficacy in controlling populations of the pathogen Ea on detached crab apple flowers as well as 
reducing blossom blight on mature apple trees [160, 164]. The suppressive action of E325 on the 
pathogen was proposed to be competition for space and nutrients in apple and pear blossoms and 
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secretion of a metabolite inhibiting pathogen growth [160]. However, suppression of fire blight by 
E325 has been inconsistent in the orchard trials due to the growth-limiting environments of field 
conditions, such as water and nutrient availability, temperature, and UV radiation [163, 183]. 
Among those, water availability is the key factor in the competition for space and nutrients between 
pathogen and antagonists, which is closely associated with relative humidity (RH) and temperature 
[150, 163]. Generally, higher RH and lower temperature may prolong the moist condition of floral 
organs, thereby accelerating bacterial growth, whereas lower moisture and higher temperature 
conditions shorten the period of wet exudates [163]. Yet, even in arid regions, the pathogen easily 
reaches maximum populations per flower and such high population growth increases the risk of 
infection through its deposition on the hypanthium where infection generally occurs [156, 184]. 
Therefore, before widespread invasion of the pathogen, the antagonists must procure the water 
required for colonizing the hypanthium, even in unfavorable environmental conditions. Another 
obstacle in employing antagonists is to maintain their viability and activity during freeze-drying 
and storage prior to orchard application. Although it would be achieved by encapsulation of 
microorganisms, only a few studies on probiotics have been reported in the literature and none on 
encapsulated plant antagonists [185-188]. In addition, lyophilization of antagonists in the presence 
of lyoprotectants such as polysaccharides, disaccharides, glycerol, and skim milk, and with 
preadaptation in saline, could provide better protection against the freezing, desiccation, and 
hyperosmotic stresses [189-191]. Previously, we reported the microencapsulation of E325 for the 
biocontrol of fire blight, demonstrating the release of E325 cells in a controlled manner [86]. 
Herein, we investigated the effectiveness of water retentivity and physical protection of alginate 
microcapsules (AMCs) on maintaining/increasing the population size of encapsulated E325 cells 
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and releasing them to suppress the pathogen strain Ea153 on floral surfaces in moisture-poor 
environments, and the survival of freeze-dried E325 encapsulated in AMCs for long-term storage.    
 
6.2. Materials and Methods 
6.2.1. Materials 
P. Sodium alginate, Tween 20, sodium citrate, CaCl2, glycerol, trehalose, and maltodextrin 
were purchased from Sigma-Aldrich (Milwaukee, WI, USA). Luria-Bertani (LB) broth and agar 
were purchased from Fisher Scientific (Waltham, MA USA) and BD (Franklin Lakes, NJ, USA), 
respectively. All chemicals were used without further purification. 
6.2.2. Bacterial Strain and Culture Conditions and Plant Material 
P. agglomerans strain E325 was originally isolated from Gala apple blossoms in orchards 
near Wenatchee, WA, in 1994 [156]. The primary pathogen used in this experiment was E. 
amylovora strain Ea153, obtained from K. Johnson (Oregon State University, Corvallis). E325 and 
Ea153 are resistant to rifampicin and nalidixic acid, respectively. Strain E325 was transformed 
with a plasmid carrying the rfp-gene (pMP4662) [176]. E325 labeled with rfp was used to allow 
ex vivo observation of the antagonist on viable plant tissues without any staining. The bacteria 
were stored in 15% glycerol at −70 °C, and initially incubated in LB broth containing 10 g/l 
tryptone, 5 g/l yeast extract, and 5 g/l sodium chloride in dH2O, for 24 h at 28 °C on an orbital 
shaker at 150 rpm. Cells in the medium were diluted with an alginate solution for 
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microencapsulation. Bacterial levels in the final alginate solution were estimated at 1.6 x 109 
colony forming units (CFU) per ml by dilution plating on LB plates at 28 °C for 24 h. 
Laboratory experiments were performed with detached blossoms of apple cultivar Gala 
(Malus × domestica). Trees were induced to bloom in a greenhouse as previously described [156]. 
Newly opened flowers were collected and maintained by submerging the cut end of the pedicle in 
10% sucrose contained in each tube. Tubes with flowers were supported by plastic racks placed in 
a plastic container. RH was controlled by flooding the bottom of the container with varying 
concentration of glycerol solution in dH2O, covered with a lid [192]. 
6.2.3. Microencapsulation 
E325 microencapsulation was performed by the PPF method previously described [86]. 
Briefly, two 1.0% (w/v) alginate solutions were prepared and filtered through cellulose acetate 
membranes with pore sizes of 0.8, 0.45, and 0.22 μm, consecutively. LB broth of 0.5% (w/v) 
containing cells was added to one of the solutions and used as core solution. The solutions were 
fed separately into the coaxial nozzle of the PPF system to produce a jet, which was broken up 
into uniform core/shell drops by acoustic excitation. The resulting droplets were gelled in a bath 
containing 100 mM CaCl2 and 0.05% (w/v) Tween 20 (pH 7.2-7.4) for 10 min. The resulting 
AMCs containing E325 cells were washed three times with sterile water before each experiment. 
6.2.4. Moisture Retention of AMCs 
As-prepared AMCs were placed on polystyrene petri dishes without lids and kept at 25 °C 
and 20, 40, 60, and 75% RH. The moisture retention of AMCs was calculated by the following 
equation: 
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Moisture retention (%) = ௦ܹ − ௗܹ௜ܹ − ௗܹ  × 100 
where Ws is the weight of AMCs at each scheduled time point, Wi the initial weight of AMCs and 
Wd the weight of AMCs dried under vacuum for 24 h. 
6.2.5. In Vitro/Ex Vivo Survivability of Encapsulated E325 at Various Relative 
Humidities 
A total of 18,000 E325-encapsulating AMCs were transferred to each polystyrene dish 
containing no medium, i.e., 2.36 x 106 CFU of E325 per dish, at 25°C with 20, 40, 60, and 75% 
RH. At scheduled time points, the AMCs in each sample were added to 150 mM sodium citrate 
solution. Initial counts of the encapsulated bacteria were determined immediately after 
microencapsulation. For ex vivo observation, the E325-encapsulating AMCs suspended in sterile 
water were applied on the surfaces of stigmas, anthers, and hypanthium and incubated at 25 °C 
and 65% RH. Stigmatic colonization of rfp-E325 released from the AMCs was examined under a 
fluorescence microscope (Olympus BX51, Olympus America Inc., Waltham, MA, USA). For 
quantitative assessment of E325 population, the E325-encapsulating AMCs (1.1 × 104 CFU/flower) 
on apple flowers were incubated at 25 °C and 40, 65, and 90% RH. At scheduled time points, after 
removing petals, five flowers per treatment were placed in sterile tubes containing a 150 mM 
sodium citrate solution. Each tube was vortexed and placed in a sonication bath for 1 min. After 
removing flowers, each tube containing E325 was again vortexed, and serial dilutions were spread 
on selective media.  
 83 
6.2.6. Ex Vivo Assessment of AMC-Mediated Treatment 
Naked or encapsulated E325 (104 CFU/flower) was applied to the Gala apple flowers, 
which were placed in the humidity chambers and incubated at 25 °C with 40 and 65 % RH. After 
24 h, strain Ea153 (104 CFU/flower) was applied to the flowers. As controls, naked E325, 
encapsulated E325 and Ea153 (104 CFU/flower) were separately applied to the flowers. At 
scheduled time points, five flowers per treatment were sampled to determine each bacterial 
population size on selective media.  
6.2.7. Lyoprotection and Osmoadaptation of Encapsulated E325 and Long-
Term Storage 
Trehalose of 20% and maltodextrin solutions of 20% (w/v), and a combination of 10% 
trehalose and 10% maltodextrin solutions were prepared and sterilized by autoclaving. Each 
solution was combined with E325-encapsulating AMCs and transferred into sterilized vials (4,500 
capsules/vial), kept at −70 °C overnight, and freeze-dried at −50 °C using a Unitop 400 L (Virtis, 
PA) under < 1 Pa. The AMCs freeze-dried without any lyoprotectant were prepared as a control. 
The freeze-dried capsules were rehydrated in DI water at 25 °C for 10 min and liquefied using 150 
mM sodium citrate solution. The survivability of E325 in these capsules was assessed by six 
replicate measurements. This process was repeated after adding 0.1 – 0.3 M NaCl to the AMCs 
with 10% trehalose and 10% maltodextrin solutions. The survival rate was calculated as a ratio of 
the cell density at each time point to the initial density of the cells survived from freeze-drying. 
E325 survival in the freeze-dried AMCs, stored at −20 °C, was measured at scheduled time points 
of 0, 3, 7, 14, 21, 28, and 42 days. 
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6.2.8. Statistical Analysis 
Data are expressed as mean values ± SD in n independent observations. Data comparisons 
were performed by one-way ANOVA and paired two-tailed Student’s t tests in case of multiple 
comparisons. Differences with p < 0.05 were considered statistically significant. 
 
6.3. Results 
6.3.1. Microencapsulation 
E325 was encapsulated in AMCs of 80 μm diameter to ensure their facile coverage of the 
main target sites, i.e., the stigmatic (< 1 mm2) and hypanthial (2–3 mm2) surfaces of flower. Figure 
6.1 shows the optical images of the E325-encapsulating AMCs prepared by the PPF method, 
illustrating that the E325 cells multiply inside the capsule as a function of time. 
6.3.2. Moisture Retention of AMCs and In Vitro Survivability of Encapsulated 
E325 at Various RH 
Figure 6.2(a) shows the water retention property of the AMCs was determined under 20, 
40, 60 and 75% RH conditions at 25 °C, displaying that the evaporation of water from the AMCs 
increased with decreasing RH during the 3-day period. After 12 h, the water retention at 20 and 
75% RH was <30% and 65%, respectively. Under all RH conditions, about 90% water was 
evaporated from the AMCs after 72 h. Figure 6.2(b) shows the survival of encapsulated E325, i.e., 
the sum of cells released from and remaining in the AMCs, as a function of time at different RH 
conditions, indicating that the E325 survival decreased with decreasing RH that is associated with 
 85 
the water retentivity of the AMCs. It was intriguing that the encapsulated cells exhibited a 
meaningful survivability even at low RH values (< 40%) for 2 days.  
6.3.3. Ex Vivo Survivability of Encapsulated E325 
Figure 6.3(a) and (b) show the optical images of a detached blossom of Gala apple after 
applying the E325-encapsulating AMCs, revealing that the capsules landed on the surfaces of 
stigmas, anthers and hypanthium. After 3 days at 65% RH, the AMCs applied on stigmas and 
anthers shrank and became yellowish in color caused by the evaporation of water. The fluorescence 
image of the stigma taken 3 days after applying the AMCs encapsulating rfp-labeled E325, shows 
that the cells proliferated inside the capsules and egressed to cover the stigmatic surface [86, 176]. 
Figure 6.3(c) shows the effect of encapsulation on the survival of E325, assessed by applying 
naked E325 (E325-naked) and E325 encapsulated in AMCs (E325-AMCs) on the floral surfaces 
of Gala apple at 40, 65 and 90% RH. At 65 and 90% RH, the population sizes of both E325-naked 
and E325-AMCs, with an initial cell number of 104 CFU/flower, increased exponentially during 
the initial 24 h. Especially, for E325-AMCs at 90% RH, the increase was so large that the 
population size exceeded 108 CFU. After 24 h, the population was maintained or increased for 
both groups. On the other hand, at 40% RH, both groups displayed a minimal increase during the 
24 h period, followed by a decrease. However, E325-AMCs exhibited a higher population size 
than E325-naked at each time point.  
6.3.4. Ex Vivo Assessment of AMC-Mediated Treatment 
To investigate the suppressive activity of E325-naked and E325-AMC, Ea153 was applied 
to detached Gala apple blossoms that had been inoculated with each type of E325 and incubated 
for 24 h. Figure 6.4 shows the suppressive activity of E325-naked and E325-AMC against Ea153. 
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When incubated at 25°C / 65 and 40% RH, populations of E325-naked, E325-AMC and Ea153 
increased during the initial 24 h; thereafter, they remained relatively constant at 65% RH, but 
decreased at 40% RH. At both 65 and 40% RH, the populations of E325-AMC were greater than 
those of E325-naked with or without the application of Ea153 (Figure 6.4(a) and (b)). At 65% RH, 
the population sizes of both E325-naked and E325-AMC increased with time regardless of the 
Ea153 application, and the difference between the E325 population size with and without Ea153 
application was small during the 72-h period. However, at 40% RH, the difference was quite 
substantial at 72 h. Figure 6.4(c) and (d) show that the population sizes of Ea153 were reduced by 
the pre-application of E325-AMC or E325-naked, but more substantially by the former. During 
the period from 36 (or 12 h after inoculation with Ea153) to 72 h, the reduction in the Ea153 
population caused by E325-AMC was significantly greater than that by E325-naked. Interestingly, 
the suppressive activity of E325-AMC against Ea153 was more effective at 40% RH as compared 
to E325-naked, lowering the population of Ea153 to <103 CFU.  
6.3.5. Survival of Encapsulated E325 during Lyophilization 
Lyophilization is considered to be the method that best maintains cell viability during 
storage [193]. However, when the E325-encapsulating AMCs were lyophilized without any 
lyoprotectants, the survival of the E325 cells reduced to 27.8 ± 8.1%. Figure 6.5(a) shows the 
effect of lyoprotectants, trehalose and maltodextrin (MD), on the survival of the E325 cells during 
freeze-drying with or without the use of NaCl. In the presence of 20% (w/v) trehalose or MD, the 
cell survivability increased to 44.8±10.6 or 67.3±6.5%, respectively, without NaCl. The increase 
was more significant when both trehalose and MD were incorporated into the AMCs, reaching 
85.5 ± 7.9%. Interestingly, no significant difference was observed between the absence and 
presence of 0.1M NaCl. Under this condition, the cell survival was 93.0 ± 9.6%, which decreased 
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when the concentration of NaCl increased to 0.3M. Figure 6.5(b) illustrates the survival rate of the 
AMC-encapsulated E325, freeze-dried and stored at −20 °C for 42 days. The survival rates were 
calculated by comparing with the initial cell densities, survived from freeze-drying, which was 
considered to be 100%. In the absence of lyoprotectants, the cell survival reduced rapidly to 
34.2±7.6% after storing for 21 days and 0% for 28 days. In the presence of lyoprotectants, with or 
without 0.1M NaCl the survivability of the lyophilized cells was maintained at 94.8±2.8 or 
89.3±6.1% after 21 days, and 73.5±6.7 or 64.5±2.8% after 42 days, respectively. 
 
6.4. Discussion 
The tree invasion of Ea starts with colonization on the flower surfaces during petal 
expansion which typically lasts 3 to 4 days. A moisture- and nutrient-rich environment of stigmatic 
papillae allows bacterial cells to colonize even under arid climatic conditions. Rain or heavy dew 
facilitate the cell movement along the floral style toward the nectarthodes of hypanthium, the main 
infection site of fire blight [150]. Therefore, tolerance to abiotic factors such as temperature, water 
availability and RH is a prerequisite for ecologically competent antagonists against pathogens. But, 
on a typical spring day when temperature rises and RH decreases, antagonists landing on floral 
surfaces excluding stigmas, e.g., hypanthium, anthers and petals, are subject to desiccation and 
decrease in the conventional biocontrol management. In moisture- and nutrient-poor environment 
such as polystyrene, the abundance of hydroxyl groups in the alginate matrix contributed to 
maintaining water molecules within AMCs for 3 days under various RH conditions (Figure 6.2(a)) 
[194]. The survival of the E325 encapsulated in AMCs was maintained for > 2 days even at 20% 
RH (Figure 6.2), implying the prolonged survivability of E324 by the AMCs on moisture-poor 
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surfaces of flower. The maximum population size of bacterial strains in the detached Gala apple 
blossoms, such as A506, C9-1 and Ea153, was reported to be between 106 and 107 CFU [156]. As 
shown in Figure 6.3(c), the population sizes over 107 indicate that the E325 cells continuously 
multiply in the moisture- and nutrient-rich environment of the AMCs, and thus the released cells 
colonize on floral surfaces even under low RH conditions. It is as if each flower has its own micro-
incubators supplying E325. To date, the delivery of antagonists has been focused on targeting the 
flower stigmas due to their moisture- and nutrient-rich environment [156, 181, 182, 195]. 
Considering that the main infection site is hypanthium, the AMC-mediated delivery of antagonists 
may target the entire floral surfaces, including hypanthium, to increase their efficacy to prevent Ea 
invasion by providing water and nutrients required for bacterial multiplication and colonization. 
This does not require a long and difficult journey for antagonists to migrate toward hypanthium 
via stigmatic colonization. In fact, the encapsulated E325 showed a significantly improved 
suppressive activity against Ea153 at both 40 and 65% RH, compared to the naked E325 (Figure 
6.4). Furthermore, the AMC-mediated E325 delivery exhibited a high efficacy even at 40% RH. 
Under this condition of poor water availability, both the antagonist E325 and the pathogen Ea153 
would compete for moisture outside AMCs, and the suppressive effect of E325 against Ea153 was 
minimal. Furthermore, the AMCs-mediated delivery may increase the chance for the antagonist to 
be transferred to late-blooming or nearby flowers via rain or arthropods.  
Maintaining viability of encapsulated E325 during freeze-drying and storage is of crucial 
importance to their successful orchard application [191]. In most cases, survival after freeze-drying 
was less than 5% for Gram-negative bacteria such as E325 [188, 196, 197]. The encapsulation of 
E325 resulted in improved preservation of survivability by providing a physical barrier against 
harsh environmental conditions such as freezing, loss of cellular turgor, dehydration, and vacuum 
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stress [185-187]. Moreover, the recovery of encapsulated E325 from freeze-drying was 
significantly enhanced by employing lyoprotective agents. The survival rates of more than 80% 
obtained by the combined use of trehalose and MD could be attributed to the following: a) trehalose 
prevents cellular collapse caused by intracellular ice crystals formed during freezing and b) the 
presence of MD outside the AMCs promotes the egress of water molecules, causing intracellular 
accumulation of trehalose [198-200]. Osmoadaptation under saline stress has been employed to 
improve tolerance of bacterial cells to lyophilization and long-term storage as NaCl promotes the 
intracellular accumulation of osmolytes such as trehalose [190, 201-203]. However, our result 
exhibited no statistical difference between the survivability of encapsulated E325 after freeze-
drying with 0.1M NaCl and without. Further, when the NaCl concentration increased to 0.3M, the 
survivability decreased. Although further study is needed to understand this, we speculated that 
the hydrophilic property of the alginate hydrogel and the water egress facilitated by MD might 
have been sufficient to promote the intracellular accumulation of trehalose without NaCl.  
 
6.5. Conclusion 
P. agglomerans strain E325 was encapsulated with nutrients in the core of uniform alginate 
microcapsules of a size of 80 μm in diameter for the biocontrol of fire blight. Theses hydrogel 
capsules could prolong the survival of E325 on moisture- and nutrients-poor surfaces for 2 days, 
even at 20% RH, and consequently allow higher population sizes on the detached apple flowers 
compared to naked E325. Correspondingly, the AMC system exhibited significantly high 
suppressive activities against E. amylovora strain E153 on detached apple flowers at 40 and 65% 
RH. More importantly, the AMC-mediated efficacy was higher at lower RH as providing water 
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and nutrients exclusively to the encapsulated E325 cells. This indicates that microencapsulation of 
E325 is a promising approach for the biocontrol of fire blight under arid conditions. Moreover, the 
lyoprotection of encapsulated E325 during the inoculum preparation improved its stability and 
long-term survivability. Many microorganisms are potentially capable of promoting crop growth 
and protecting plants from adverse environmental conditions. However, the gap between their 
positive potentials and successful field application is very wide due to rapid and wide fluctuations 
in water and nutrient availabilities. The present study suggests that encapsulation of such 
biocontrol agents could be a viable strategy to apply to plants or soil for the management of fire 
blight. 
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6.6. Figures 
 
Figure 6.1 Optical images of the AMCs encapsulating E325 at 25 ºC at 0 (immediately after encapsulation), 1, 2, and 3 days. 
  
 92 
0
20
40
60
80
100
(b)
(a)
 
 
Wa
ter 
rete
ntio
n (%
)
  20%       40%       60%        75%
72631 4824120.0
3
4
5
6
Log
 CF
U p
er A
MC
s
 
 
Time (hr)  
Figure 6.2 (a) Water retention property of the AMCs of 80 μm diameter, and (b) survival of E325 
encapsulated in 18,000 AMCs (2.36 x 106 CFU) per dish on polystyrene petri dishes at 25 °C and 
20, 40, 60, and 75% RH. The initial weight of water absorbed in the AMCs was set as 100% water 
retention. Data are represented as mean ± SD (n=4).  
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Figure 6.3 (a) Optical images of stigmas, anthers and hypanthium on apple flower taken after applying the E325-encapsulating AMCs (Day 0). Blue arrows indicate the AMCs. (b) Optical image of apple flower taken at 3rd day after applying the AMCs at 65% RH. Inset shows a fluorescence image of the stigma colonization by rfp-E325 (pMP4662) released from the AMCs. 
Scale bar = 500 µm. (c) Survival of free E325 and encapsulated E325 on detached blossoms of 
Gala apple at 25 °C and 40, 65 and 90% RH during 72 h. Data are represented as mean ± SD (n=5). At 48 and 72h, different letters indicate significant differences between groups (p <0.05). 
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Figure 6.4 (a,b) Survival of E325 (E325-naked) or encapsulated E325 (E325-AMC) against E153 and (c,d) Ea153 against E325-naked or E325-AMC on detached blossoms of Gala apple under at 65% (a,c) and 40% (b,d) RH. As controls, naked E325, encapsulated E325 and Ea153 (104 
CFU/flower) were separately applied to the flowers. Data are represented as mean ± SD (n=5). * 
denotes a statistically significant difference between the populations of E325 and E325-AMC with E153 or without (a,b) and those of Ea153 with E325 or E325-AMC (c,d), *p <0.05, **p <0.005, and ***p <0.001. At 48 or 72 h, different letters indicate significant differences between groups (p <0.05). 
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  Figure 6.5 (a) Effect of trehalose (Tre) and maltodextrin (MD) as lyoprotectants on the survival of the encapsulated E325 cells in the absence or presence of NaCl during freeze-drying. (b) Effect of the combined use of trehalose (Tre) and maltodextrin (MD) as lyoprotectants on the survival of freeze-dried E325 cells during the storage period of 42 days. The AMCs freeze-dried without any lyoprotectants served as a control. The mean population size that was initially encapsulated was 
set as 100%. Data are represented as mean ± SD (n=6). * denotes a statistically significant 
difference as compared to initially encapsulated E325, *p <0.05, **p <0.005, and ***p <0.001. Different letters indicate significant differences between groups (p <0.05).  
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CHAPTER 7 
CONCLUSIONS AND FUTURE WORK 
 
Microencapsulation of therapeutic cells and fabrication of drug-loaded microspheres for 
controlled release have been of great significance and interest in the pharmaceutical and food 
industries as well as in agriculture, biotechnology, and medicine. However, the conventional 
methods of generating microcapsules and microspheres have major obstacles before clinical trials 
in terms of reproducibility and controllability of size, uniformity, sphericity, permeability, cell 
protrusion, and throughput. In this dissertation work, we have investigated various applications of 
MCs and MSs prepared by the PPF method and demonstrated that the method is applicable to any 
drug delivery system designed for biological purposes. My thesis advisor, Professor Kyekyoon 
(Kevin) Kim, is the original developer of the PPF system. He and his colleagues including 
Professor Hyungsoo Choi have fabricated a variety of MCs and MSs using various natural and 
synthetic polymers. As extended work, we have demonstrated the feasibility and flexibility of the 
PPF method in practical cell encapsulations.  
The PPF method was evolved enabling a single-step fabrication of uniform MCs of 
controlled size and shell thickness of highly viscous alginate solutions, with diameters of 120 – 
510 μm at a production rate of 1,000 drops/sec. Precise control of the volumetric flow-rates of the 
core and shell fluids allowed custom-tailored core/shell structures, while optimizing the cell 
confinement in the core. NIH 3T3 fibroblasts or human and pig islets encapsulated by this method 
exhibited no cell protrusion or decrease in their viability. As for the clinical significance of 
controlled release systems, monodisperse MSs and core/shell MCs offer advantages in 
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reproducibility, controllability, and most importantly, relative insensitivity to the choice of 
materials, which provides valuable assistance and flexibility in designing advanced drug delivery 
systems.  
In order to induce balanced cell-cell and cell-substrate interactions that are critical for long-
term survivability and function of therapeutic cells in cell-based therapy, MSs were co-
encapsulated with the cells in the semi-liquid core of the MCs. MSs acted as anchors to provide 
an expanded surface area for the cells to adhere and to proliferate. As a result, through optimization 
and alteration of intracapsular microenvironment, the co-encapsulation of MSs and cells increased 
the survival of the encapsulated cells via enhanced cell-substrate interactions. Based on this 
strategy, we co-encapsulated porcine islets with exenatide-loaded MSs for application to treatment 
of diabetes. Exenatide-loaded MSs prepared by the PPF method allowed narrow size distribution, 
and high loading amount and efficiency, exhibiting constant release of exenatide over extended 
periods of time. The alginate MCs system co-encapsulating porcine islets with the exenatide-
loaded MSs allowed improved islet survival and function during the designed time, suggesting that 
the proposed concept potentially could not only alleviate the adverse effects of exenatide by its 
local secretion around islets but also resolve the problem of donor shortage and graft-related 
complications by reducing the transplanted islet mass. With mono- or muti-functional 
microparticles reported in the literature, the co-encapsulation system could be applied to various 
cell-based therapies beyond islet xenotransplantation. 
As a delivery system for biological control of fire blight, microencapsulation and controlled 
release of the bacterial antagonist P. agglomerans strain E325 were investigated using core-shell 
alginate MCs. The described strategy of encapsulating bacterial cells demonstrated the following 
capabilities: (1) fabrication of precisely size-controlled alginate capsules 60 to 300 μm in diameter, 
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(2) achievement of custom-tailored core-shell structures by single-step processing without 
producing empty capsules or damaging cells, and (3) controlled profiles of cell release from the 
MCs by separately adjusting alginate concentrations of the core and outer solutions in the PPF 
system. Furthermore, E325 was co-encapsulated with nutrients into uniform core-shell MCs of 80-
100 μm diameter to examine the feasibility of employing E325-encapsulating MCs in field 
applications exposed to rapid and wide fluctuations in moisture and nutrient levels. With optimized 
environment in the MCs, the MC-mediated delivery system exhibited the release of large 
population sizes of E325 at various relative humidity levels, resulting in enhanced suppressive 
activities against E. amylovora strain E153. Moreover, to maintain viability and activity during 
freeze-drying and storage prior to orchard application, the effects of lyoprotection and 
osmoadaptation of encapsulated E325 during the product preparation were investigated. The 
results suggest that microencapsulation of such biocontrol agents can be considered as a feasible 
strategy for future applications to plants or soil beyond fire blight management. 
In conclusion, we have demonstrated the flexibility and feasibility of the PPF method in 
producing precisely controlled MCs and MSs and its suitability for biological applications 
involving therapeutic cell delivery for xenotransplantation and controlled antagonist release for 
plant disease management.  
In this dissertation work, a number of excellent capabilities of the PPF method were 
described and demonstrated for cell encapsulation and fabrication of MCs/MSs. These 
characteristic advantages will have a major impact on the clinical trials employing MCs and MSs 
containing therapeutic agents. Continued study with PPF may include the following: (1) 
encapsulation of various cell sources such as stem cells, progenitor cells, and genetically 
engineered cells and fabrication of MSs containing therapeutic proteins or genes, (2) 
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functionalization of MCs or MSs for various biological purposes, e.g. immobilization of ligands 
for target delivery, recognizing specific receptors on the surface of diseased or damaged sites,  (3) 
effective protection from provoking host’s immune reaction, and (4) visualization of MCs or MSs 
at the target site for both diagnostics and efficient drug therapy. Since the MCs or MSs produced 
by the PPF method could serve as customized drug delivery vehicles capable of carrying sufficient 
cargo of therapeutic agents into the sites of interest, their functionalization for target delivery and 
visualization would contribute to development of advanced delivery systems for elucidating 
underlying disease mechanisms as well as guiding the pre- and post-treatment assessment. 
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